56th Annual Meeting of the Scientific and Standardization Committee of the ISTH

22 May – 25 May 2010
Cairo, Egypt / Grand Hyatt

www.ssc2010.org
TRANSFORMING
Anticoagulation with no injections or monitoring\textsuperscript{1,2}

This information was approved for the UK. Please check for the most current version as approved for your country.

Prescribing Information (UK) - PRADAXA\textsuperscript{®}
Capsules containing 75 mg or 110 mg dabigatran etexilate (as mesilate)

Action: Direct thrombin inhibitor
Indication: Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip or knee replacement surgery. Dose and administration: Initial dose 110 mg within 1-4 hours of completed surgery, then 220 mg once daily. In moderate renal impairment (Cr CI 30-50 ml/min) or patients \(\geq 75\) years reduce dose: initial dose 75 mg, then 150 mg once daily. After knee replacement surgery continue treatment for a total of 10 days; after hip replacement surgery for 28-35 days. Delay initiation of treatment if haemostasis is not secured. If treatment is not started on the day of surgery initiate with 220 mg (or 150 mg) once daily.

Contra-indications: Hypersensitivity to any component; severe renal impairment (Cr CI \(< 30\) ml/min); clinically significant bleeding; organic lesion at risk of bleeding; impairment of haemostasis; hepatic impairment or liver disease expected to have any impact on survival; concomitant quinidine

Warnings & precautions: Not recommended if liver enzymes > 2 ULN; measure ALT in pre-operative evaluation. Close clinical surveillance (signs of bleeding or anaemia) is recommended throughout the treatment period, especially when haemorrhagic risk is increased: diseases associated with a risk of bleeding such as coagulation disorders, thrombocytopenia or functional platelet defects, active ulcerative GI disease, recent biopsy or major trauma, recent ICH or brain, spinal or ophthalmic surgery, bacterial endocarditis, concomitant NSAIDs (\(\geq 12\) hours), concomitant strong P-glycoprotein inhibitors (e.g. verapamil, amiodarone). Patients \(< 50\) kg or \(\geq 110\) kg; the elderly, patients at high surgical mortality risk and with intrinsic risk factors for thromboembolic events. If severe bleeding occurs, discontinue treatment and investigate the source of the bleeding. Avoid or use with caution agents which may increase the risk of haemorrhage. Not recommended in patients undergoing anaesthesia with postoperative indwelling epidural catheters; the first dose should be given a minimum of 2 hours after catheter removal; these patients require frequent observation for neurological signs and symptoms. Contains Sunset Yellow (E110) which may cause allergic reactions. Interactions: Anticoagulants and platelet aggregation agents; amiodarone (reduce Pradaxa dose to 150 mg); verapamil (reduce Pradaxa dose to 150 mg) (consider dose reduction to 75 mg daily in patients with both moderate renal impairment and on verapamil); close monitoring with clarithromycin; caution with strong P-glycoprotein inhibitors or inducers (e.g. rifampicin, St John’s wort). Pregnancy and lactation: Avoid pregnancy during treatment. Do not use in pregnancy unless clearly necessary. Discontinue breast-feeding during treatment.

Undesirable effects: Most common is bleeding (14%); major bleeds, including wound site bleeding, < 2%. Common (\(\geq 1/100\), <1/10): anaemia; haematoma; decreased haemoglobin; wound incision, postoperative or postprocedural anaemia, postprocedural discharge. See SPC for details of these and other undesirable effects.

Pack sizes, NHS price and MA numbers: 75 mg: 10 capsules £21.00 EU/1/08/442/001; 60 capsules £126.00 EU/1/08/442/003 110 mg: 10 capsules £21.00 EU/1/08/442/005; 60 capsules £126.00 EU/1/08/442/007. Legal category: POM Marketing Authorisation Holder: Boehringer Ingelheim International GmbH, D-55216 Ingelheim am Rhein, Germany. Prescribers should consult the Summary of Product Characteristics for full prescribing information. Prepared in December 2009.

References

Pradaxa\textsuperscript{®}
dabigatran etexilate
Transforming anticoagulation
# Table of Contents

Meeting Sponsors ......................................................... 2
Welcome Message from the Meeting President ................. 3
Welcome Message from the SSC Chairman ....................... 4
Committees ................................................................. 5
ISTH Future Meeting Calendar ......................................... 9
Awards and Grants 2010 ................................................. 10
General Information ..................................................... 15
Guidelines for Chairmen and Speakers .......................... 23
Floor Plan ................................................................. 25
Program at a Glance ...................................................... 27
Educational Sessions ................................................... 31
SSC Scientific Subcommittee Sessions –
  Overview ................................................................. 34
  Detailed Program (Sunday) .......................................... 35
  Detailed Program (Monday) ........................................ 42
  Detailed Program (Tuesday) ....................................... 57
Symposia Schedule – Overview and Programs ............... 68
Sponsor & Exhibitor Profiles ......................................... 75
Exhibition Floor Plan .................................................... 86
Exhibitors ................................................................. 87
Meeting Sponsors

The ISTH would like to thank the following companies for their generous support of the society’s 56th Annual Meeting of the Scientific and Standardization Committee.

Platinum Sponsor: Baxter

Gold Sponsors:

Silver Sponsor:

Bayer Healthcare
Bayer Schering Pharma

Bronze Sponsors:

CSL Behring
Biotherapies for Life™

Haematologic Technologies Inc.

Siemens

Inverness Medical

Stago
Welcome Message from the 56th SSC Meeting President

Dear Colleagues and Friends,

From the glorious city of Cairo, it is my great pleasure to welcome you all to the 56th Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH).

In addition to the SSC’s Program with the Scientific Subcommittees; Working Group presentations; and sponsored Satellite Symposia, we have dedicated 20 hours of the meeting for education, featuring presidential lectures, interactive sessions, debates and Meet-the-Expert sessions. 21 hours of CME certification are available through EACCME. For the first time in the history of any ISTH Congress or SSC Meeting, the educational sessions will be webcast and will extend the educational benefits to meeting attendees and ISTH members.

Cairo provides an unforgettable setting for the 56th SSC Meeting. Here you will find over 7000 years of a continuum of history in one place, carrying you over the centuries as you move from site to site. Still again, this history is mixed with modern entertainment which will carry you off to the 21st century amidst the mist of oriental charm.

I would like to thank our corporate sponsors and exhibitors for their generous support. I would also like to thank the members of our Organizing Committee for their help and also the headquarters of the ISTH for their tremendous help and encouragement.

We welcome you all in the 56th SSC meeting in Cairo; you have a place in our hearts.

Nevine Kassim, MD
President
56th SSC Annual Meeting
Dear Colleagues,

Welcome to Cairo! It is with great pleasure that I greet you here on the banks of the River Nile to carry on the wonderful tradition of annual international scientific dialogue sponsored by the Scientific and Standardization Committee of the ISTH.

In this first meeting of the SSC in Africa, we are making history and expanding opportunities for personal interaction with colleagues in the region. President Nevine Kassim and her local Organizing Committee have made careful preparations to make your visit to Egypt pleasant and valuable culturally as well as scientifically. Beginning with the excellent Educational Program and continuing through the Plenary Lectures, Symposia and Subcommittee Meetings, opportunities for learning and for sharing of scientific and clinical information abound.

And the rich cultural history of Egypt awaits your exploration.

Best wishes for a valuable and enjoyable meeting and stay in Cairo.

Sincerely,

Gerhard J. Johnson, M.D.
Chairman
Scientific and Standardization Committee
ISTH
Committees

Organizing Committee
Nevine Kassim, President
Hadi Goubran
Magdy El Ekiaby
Sherief Sholkami

Scientific and Standardization Committee

Chairman (2008–2010) Gerhard J. Johnson (USA)
Chairman-elect (2008–2010) Anna Falanga (Italy)
Special Assistant to the Chairman (2008–2010) Nuala Ann Booth (UK)
Executive Officer Bruce Furie (USA)

Terms Ending 2010
Dermont Kenny (Republic of Ireland)
Claude Negrier (France)
Edward GD Tuddenham (UK)
AMHP Van Den Besselaar (The Netherlands)
### Committees (Continued)

#### Subcommittees of the Scientific and Standardization Committee

<table>
<thead>
<tr>
<th>Subcommittee</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animal, Cellular &amp; Molecular</td>
<td>Timothy C. Nichols (USA)</td>
</tr>
<tr>
<td>Models of Thrombosis</td>
<td></td>
</tr>
<tr>
<td>Biorheology</td>
<td>Johan W.M. Heemskerk (The Netherlands)</td>
</tr>
<tr>
<td>Control of Anticoagulation</td>
<td>Trevor Baglin (UK)</td>
</tr>
<tr>
<td>DIC</td>
<td>Hideo Wada (Japan)</td>
</tr>
<tr>
<td>Exogenous Hemostatic Factors, Registry of Factor VIII &amp; Factor IX</td>
<td>Mary Ann McLane (USA)</td>
</tr>
<tr>
<td>Factor XIII &amp; Fibrinogen</td>
<td>Hans P. Kohler (Switzerland)</td>
</tr>
<tr>
<td>Fibrinolysis</td>
<td>Colin Longstaff (UK)</td>
</tr>
<tr>
<td>Hemostasis &amp; Malignancy</td>
<td>Agnes Y.Y. Lee (Canada)</td>
</tr>
<tr>
<td>Lupus Anticoagulant/Phospholipid-dependent Antibodies</td>
<td>Thomas L. Ortel (USA)</td>
</tr>
<tr>
<td>Perinatal/Pediatric Thrombosis and Haemostasis</td>
<td>Paul Monagle (Australia)</td>
</tr>
<tr>
<td>Plasma Coagulation Inhibitors</td>
<td>Herbert Whinna (USA)</td>
</tr>
<tr>
<td>Plasma Kallikrein-Kinin System</td>
<td>Thomas Renne (Sweden)</td>
</tr>
<tr>
<td>Platelet Immunology</td>
<td>Andreas Greinacher (Germany)</td>
</tr>
<tr>
<td>Platelet Physiology</td>
<td>Marco Cattaneo (Italy)</td>
</tr>
<tr>
<td>Predictive Hemostatic Variables and Cardiovascular Disease</td>
<td>James Douketis (Canada)</td>
</tr>
<tr>
<td>Vascular Biology</td>
<td>Françoise Dignat-George (France)</td>
</tr>
<tr>
<td>Von Willebrand Factor</td>
<td>Jeroen C.J. Eikenboom (The Netherlands)</td>
</tr>
<tr>
<td>Women’s Health Issues in Thrombosis and Haemostasis</td>
<td>Sabine Eichinger (Austria)</td>
</tr>
</tbody>
</table>
Committees (Continued)

International Society on Thrombosis and Haemostasis

Officers

Chairman of Council
Frits R. Rosendaal (The Netherlands)
(2008–2010)

Secretary/Chairman-elect
Henri Bounameaux (Switzerland)
(2008–2010)

President of
XXIII ISTH Congress
Yasuo Ikeda (Japan)

Vice President of
XXIII ISTH Congress
Akira Yoshioka (Japan)

Council Members

Class of 2010
Ph. G. de Groot (The Netherlands)
D. Lane (UK)
I. Peake (UK)
U. Seligsohn (Israel)
D. Wagner (USA)

Class of 2012
M. Berndt (Australia)
H. Bounameaux (Switzerland)
A. Nurden (France)
B. Østerud (Norway)
P. Reitsma (The Netherlands)

Class of 2014
N.A. Booth (UK)
J.-M. Freyssinet (France)
N. Key (USA)
R. Montgomery (USA)
H. ten Cate (The Netherlands)
**Committees (Continued)**

**Ex-Officio Council Members**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Officer</td>
<td>Bruce Furie</td>
<td>USA</td>
</tr>
<tr>
<td>Co-Editors, <em>Journal of Thrombosis and Haemostasis</em></td>
<td>Mike Greaves</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>David Lane</td>
<td>UK</td>
</tr>
<tr>
<td>Chairman, Scientific and Standardization Committee</td>
<td>Gerhard J. Johnson</td>
<td>USA</td>
</tr>
<tr>
<td>Special Assistant to the Chairman of Council</td>
<td>Ian R. Peake</td>
<td>UK</td>
</tr>
<tr>
<td>Past Congress Presidents</td>
<td>Bruce and Barbara Furie</td>
<td>USA</td>
</tr>
<tr>
<td>Chairman-Elect, Scientific and Standardization Committee</td>
<td>Anna Falanga</td>
<td>Italy</td>
</tr>
</tbody>
</table>
ISTH Future Meeting Calendar

XXIII ISTH Congress
with 57th Annual SSC Meeting
Yasuo Ikeda, President
Kyoto, Japan
July 23–28, 2011
www.isth2011.com

58th Annual SSC Meeting
Cheng-Hock Toh, President
Liverpool, UK
June 27–30, 2012

XXIV ISTH Congress
with 59th Annual SSC Meeting
Frits R. Rosendaal, President
Amsterdam, The Netherlands
June 29–July 4, 2013

XXV ISTH Congress
with 61st Annual SSC Meeting
Sam Schulman, President
Toronto, Canada
2015

XXVI ISTH Congress
with 63rd Annual SSC Meeting
Johannes Oldenburg, President
Berlin, Germany
2017
Awards and Grants 2010

Pier M. Mannucci Awards

These annual prizes for best articles by young investigators under the age of 35 are awarded in honor of Prof. P.M. Mannucci, first Editor-in-Chief of the Journal of Thrombosis and Haemostasis. These awards are made possible by a generous contribution from Bayer Healthcare, and recipients are selected by a jury of JTH editors.

Recipients:

**C Baldauf** (Germany) for the article “Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis.” J Thromb Haemost 2009; 12: 2096-105

**M Kannan** (USA) for the article “Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia.” J Thromb Haemost 2009; 11: 1878-85

**T Lobo** (Brazil) for the article “Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model.” J Thromb Haemost 2009; 11: 1855-64

**A Rose** (USA) for the article “Warfarin dose management affects INR control.” J Thromb Haemost 2009; 1:94-101

## Reach the World Travel Grants

In support of the ISTH’s commitment to stimulating research and furthering education in thrombosis and hemostasis throughout the world, the 56th Annual Meeting of the Scientific and Standardization Committee is pleased to announce that the following attendees have been awarded grants to participate in this year’s meeting:

<table>
<thead>
<tr>
<th>Argentina:</th>
<th>Brazil:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soledad Negrotto</td>
<td>Daniella de Moraes Mizurini</td>
</tr>
<tr>
<td></td>
<td>Roberto José Castro Fonseca</td>
</tr>
<tr>
<td></td>
<td>Stephan Nicollas Marcin Centena Goulart de Oliveira</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>China:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xia Bai</td>
</tr>
<tr>
<td>Yue Han</td>
</tr>
<tr>
<td>Shundong Ji</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Colombia:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Alzate</td>
</tr>
<tr>
<td>Julian Aristizabal</td>
</tr>
<tr>
<td>Juan Carlos Arrieta Bechara</td>
</tr>
<tr>
<td>James Samir Diaz Betancur</td>
</tr>
<tr>
<td>Viviana Olaya Colorado</td>
</tr>
<tr>
<td>Diego Gonzalez</td>
</tr>
<tr>
<td>Jhon Jaime Carvajal Gutierrez</td>
</tr>
<tr>
<td>Diana Giraldo Mendez</td>
</tr>
<tr>
<td>Diana Catalina Alzate Monsalve</td>
</tr>
<tr>
<td>Andres Rivera</td>
</tr>
<tr>
<td>Catalina Rua</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Egypt:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soha Ahmed Abu-Elela</td>
</tr>
<tr>
<td>Raghda Saad Zaghloul Ahmed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pakistan:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Munira Borhany</td>
</tr>
<tr>
<td>Arshi Naz</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Qatar:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asmaa Al-Marwani</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Russia:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temirlan Gamzatov</td>
</tr>
<tr>
<td>Alexey Arsenyev</td>
</tr>
<tr>
<td>Maria Matveeva</td>
</tr>
<tr>
<td>Ekaterina Shelest</td>
</tr>
<tr>
<td>Maria Korotkova</td>
</tr>
<tr>
<td>Alexander Shapovalov</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>South Africa:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marlien Pieters</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sudan:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fathelrahman Mahdi Hassan</td>
</tr>
<tr>
<td>Ahmed Omer Ibrahim</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Syria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tahani Ali</td>
</tr>
<tr>
<td>Haassan Almoazen</td>
</tr>
<tr>
<td>Othman Hamdan</td>
</tr>
<tr>
<td>Abir Kaddar</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ukraine:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Markiyan Soloviy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Yemen:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdulalim M.A. Malek</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Yugoslavia:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milena Jovic</td>
</tr>
</tbody>
</table>
Awards and Grants 2010 (Continued)

ISTH Young Investigator Awards

ISTH Council wishes to encourage and support the new generation of researchers and clinicians specializing in thrombosis and hemostasis by providing awards to young investigators attending this year’s SSC Annual Meeting. We are pleased to announce that the following attendees have been selected to receive ISTH Young Investigator Awards for 2010:

<table>
<thead>
<tr>
<th>Awardee:</th>
<th>Institution:</th>
<th>Country:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francois Mullier</td>
<td>UCL Mont-Godinne</td>
<td>Belgium</td>
</tr>
<tr>
<td>Kristin Krauel</td>
<td>Institut fur Immunologie and Transfusionsmedizin</td>
<td>Germany</td>
</tr>
<tr>
<td>Adrienne Kerenyi</td>
<td>University of Debrecen Medical Health Science Center</td>
<td>Hungary</td>
</tr>
<tr>
<td>Pamela Scarparo</td>
<td>Padua University</td>
<td>Italy</td>
</tr>
<tr>
<td>Roberta Palla</td>
<td>Hemophilia and Thrombosis Centre of Milan</td>
<td>Italy</td>
</tr>
<tr>
<td>Marina Panova-Noeva</td>
<td>Ospedali Riuniti Bergamo</td>
<td>Italy</td>
</tr>
<tr>
<td>Allesandra Malato</td>
<td>University of Palermo</td>
<td>Italy</td>
</tr>
<tr>
<td>Paola Van der Meijden</td>
<td>Maastricht University</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Bas de Laat</td>
<td>University Medical Center</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Maryke Kuijpers</td>
<td>Maastricht University</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Astrid van Hylckama Vlieg</td>
<td>Leiden University Medical Center</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Carla Vossen</td>
<td>University Medical Center</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Willem Lijfering</td>
<td>Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Afife Karabiyyik</td>
<td>Ankara University Medical School</td>
<td>Turkey</td>
</tr>
<tr>
<td>Didem Torun</td>
<td>Ankara University Medical School</td>
<td>Turkey</td>
</tr>
<tr>
<td>Verena Schroeder</td>
<td>LIGHT Laboratories, University of Leeds</td>
<td>UK</td>
</tr>
</tbody>
</table>
### ISTH Young Investigator Awards (Continued)

<table>
<thead>
<tr>
<th>Awardee</th>
<th>Institution</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Cordell</td>
<td>LIGHT Laboratories, University of Leeds</td>
<td>UK</td>
</tr>
<tr>
<td>Chris Jones</td>
<td>Institute for Cardiovascular and Metabolic Research, University of Reading</td>
<td>UK</td>
</tr>
<tr>
<td>Daniel Hampshire</td>
<td>Haemostasis Research Group, University of Sheffield</td>
<td>UK</td>
</tr>
<tr>
<td>Andreas Mauer</td>
<td>Rockefeller University Laboratory of Blood and Vascular Biology</td>
<td>USA</td>
</tr>
<tr>
<td>Christine Medaugh</td>
<td>Michigan State University</td>
<td>USA</td>
</tr>
<tr>
<td>Anish Sharda</td>
<td>University of Minnesota</td>
<td>USA</td>
</tr>
<tr>
<td>Megan Francis-Sedlak</td>
<td>Pritzker Institute of Biomedical Science and Engineering</td>
<td>USA</td>
</tr>
</tbody>
</table>
Have you considered submitting your research to one of the leading journals focusing on thrombosis, bleeding disorders and vascular biology?

Do you want your research published in a leading journal?
- *JTH* is the number one international speciality journal in the field
- High Impact Factor - 6.291 in 2008

Do you want your research readable AND citeable within 10 days?
- Acceptance to **OnlineAccepted** publication (peer-reviewed and accepted – but not yet copy-edited) in an average of only 10 days
- Acceptance to online publication in an average of only 54 days
- Acceptance to print publication in an average of only 62 days

Do you want your research read by an expert international audience?
- Over 330,000 full text downloads in 2009
- All ISTH Members receive the journal as part of their membership

Do you want a simple and efficient submission process?
- Online submission - visit [http://mc.manuscriptcentral.com/jth](http://mc.manuscriptcentral.com/jth)
- NEW! No submission or page charges for authors

For more information visit [www.blackwellpublishing.com/jth](http://www.blackwellpublishing.com/jth)
General Information

Accommodation
A help desk for participants who have booked their hotel accommodation in advance via Pioneer Events is located in the registration area. The staff at this counter will also help you to find and book rooms, if required.

Address
Organizing Secretariat and Exhibition Management
Pioneer Events
30 Anwar El Mofti street
Nasr City – Cairo
Egypt
Phone: + 202 24046672 + 202 24053575
Fax: + 202 24020609
E-mail: info@pioneer-events.com

Airport and Airport Transportation
Taxi and Limousine Approx. $20.00 to $25.00 to downtown, congress venue and area hotels.

Annual Business Meeting of the SSC
Tuesday, May 25, 2010  Room Farhaty A
The Business Meeting is open to all interested scientists. The agenda includes brief oral reports of the Scientific Subcommittees’ sessions; action on reports and recommendations issuing from the Subcommittees; reports of Working Parties; liaison activities; and collaborative work. For further information, contact the ISTH Secretariat at Room Akhnaton A, located on the 5th floor of the Grand Hyatt.

Banks & Automatic Teller Machines (ATM)
It is recommended that foreign currency be converted to Egyptian pounds at banks, which are usually open from Sunday to Thursday from 08:30 to 14:00. ATM branches are located inside the Grand Hyatt, which is the meeting venue, at most other hotels, and are open 24 hours a day.
General Information (Continued)

Boat ride sponsored by Leo Pharma
A traditional felucca sailboat can ferry delegates down the Nile from the Semiramis Intercontinental to the Hyatt. Small group excursions can also be reserved. For schedules and docking, inquire at the Registration Desk. Sponsored by Leo Pharma.

Business Hours
Friday is the official Egyptian weekend. Most embassies are closed Friday and Saturday, but a few close on Saturday and Sunday. Shops are generally open from 09:00 to 21:00, and some close on Sunday.

Car Parking
Available at Grand Hyatt at special rate of $10.00 for a full day

Climate
The weather in Egypt in May is usually fine. The average maximum temperature is 25–30°C, average minimum temperature is 20–23°C and humidity is low.

Coffee breaks
Complimentary coffee and tea will be served in the Exhibition Area on the sixth floor. Coffee breaks during the SUBCOMMITTEE SESSIONS on May 23–24 are scheduled between 10:30–11:30 and 16:30–17:30, and between 10:30–11:30 on May 25.

Conference Venue
Grand Hyatt Hotel
Corniche El-Nil, PO Box 2288
Garden City – Roda Island
Cairo, Egypt
Phone: +20 2 2365 1234
Fax: +20 2 2362 1927
E-mail: cairo.grand@hyattintl.com
Internet: www.cairo.grand.hyatt.com
General Information (Continued)

Continuing Medical Education
The following language was provided by the EACCME:

The 56th Annual Meeting of the SSC of ISTH is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), [www.uems.net](http://www.uems.net).

The 56th Annual Meeting of the SSC of ISTH is designated for a maximum of 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

Physicians may apply to convert EACCME credit into [AMA PRA Category 1 Credit](http://www.ama-assn.org)™ by submitting an application form (found at registration desk) and attaching an EACCME credit certificate and AMA processing fee. Forms can be mailed or faxed to the AMA using the contact information found on the application form. EACCME credit certificates can be found in the delegate bag as well as at the registration desk.

Customs
Foreign currency is allowed into and out of the country. A declaration form must be completed if objects of value such as jewelry, video cameras etc. are imported for sale.

Cyber Café sponsored by Bayer Schering Pharma AG
Free internet access will be provided at 6 terminals at The Bayer Cyber Café on the sixth floor.

Delegates Satchel
Delegates will receive their delegate satchels at the registration desk. No replacements for lost satchels are available.
General Information  (Continued)

Electricity
Electricity in Egypt is supplied at 220 v–50 Hz Ac

Exhibition
The Meeting Exhibition is located on the sixth floor.

Exhibition hours:
- Saturday, 22 May 10:00–18:00
- Sunday, 23 May 10:00–18:00
- Monday, 24 May 10:00–18:00
- Tuesday, 25 May 10:00–13:00

ISTH Secretariat
The ISTH Secretariat is located at Room Akhnaton A on the fifth floor. It is open during the regular hours of the meeting.

ISTH Headquarters
Cathy Cole, Executive Administrator
Margo Price, Director of Corporate Relations
Robert Cary Clark, Information Services and SSC Coordinator

After the meeting:
International Society on Thrombosis and Haemostasis
610 Jones Ferry Road, Suite 205
Carrboro, NC 27510, USA

  Phone: +1 919 929 3807
  Fax: +1 919 929 3935
  E-mail: headquarters@isth.org

Language
The official language of the meeting is English. There will be no simultaneous translation. Arabic is the official language of Egypt. English is the primary second language and widely spoken. In addition, there are many speakers of French, Italian, German, and Spanish along with numerous other European languages.
General Information (Continued)

Local Currency
The official currency in Egypt is the Egyptian Pound (L.E.). It is divided into 100 Piastres.

Message Board sponsored by sanofi aventis
Located on the Fifth Floor

Mobile Telephones
Participants are kindly requested to keep their mobile phones silenced during scientific sessions.

Name Badges
Participants will receive their name badges when collecting their meeting documents. You are kindly requested to wear your name badge during all meeting events, including any social function. Please note that admission to scientific sessions is restricted to participants wearing their badges.

Passport and Visa
Egyptian consulate in country of origin and immigration authorities at the port of entry will grant entry visas. A transit visa is sufficient for a stay of less than 7 days. For up-to-date information, it is essential that inquiries be made prior to travel. Passports should be valid for at least 6 months prior to entry into Egypt.

Public Telephones
Available through the operator of Hotel and in the Hyatt Business Center on the Fifth Floor.

Public Transportation in Cairo
A network of public transportation covers several districts between Cairo and Giza. Please contact the Concierge of your Hotel for information about routes and times.
General Information (Continued)

Registration Desk
The registration desk is located in L’Auberge Du Nil on the 6th floor on Friday May 21 and Saturday May 22. Beginning Sunday May 23, the registration desk will be in the lobby on the fifth floor.

Opening Hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday</td>
<td>21 May</td>
<td>13:00 to 18:00</td>
</tr>
<tr>
<td>Saturday</td>
<td>22 May</td>
<td>07:30 to 17:00</td>
</tr>
<tr>
<td>Sunday</td>
<td>23 May</td>
<td>07:30 to 17:00</td>
</tr>
<tr>
<td>Monday</td>
<td>24 May</td>
<td>07:30 to 17:00</td>
</tr>
<tr>
<td>Tuesday</td>
<td>25 May</td>
<td>07:30 to 10:00</td>
</tr>
</tbody>
</table>

Pre-Registration
For participants who have registered in advance, please have your confirmation letter and passport at hand in case they are requested.

On-Site Registration
For participants registering and paying their registration fee on-site.

Restaurants
The Grand Hyatt contains several outlets offering different specialties, including the most prestigious restaurant in Cairo (The Revolving Restaurant), in addition to the Nubian Village offering Egyptian dishes.

Also a cruise restaurant sails for lunch & dinner daily (Marquis)

All meeting hotels are located downtown where a variety of restaurants are available.

Seat Retreat
The Haematologic Technologies Nile Seat Retreat is located in the Nile Expo exhibition area. This quiet zone sponsored by Haematologic Technologies offers delegates a place to sit, talk and enjoy a spectacular view of the Nile River.
**General Information** (Continued)

**Shopping**
Cairo is known as the shopping destination in the Middle East. A gallery shopping mall is adjacent to Meeting venue. The down town area is a 15 minute walk, where major shops are available.

**Smoking**
Please note that this is a non smoking meeting. Smoking is not permitted in or outside the meeting halls, nor in the exhibition area or foyers.

**Social Event**
On Sunday, May 23, 2010 at 19:00, the President invites delegates of the 56th Annual SSC Meeting to the Egyptian Night Reception at the Giza pyramids. Tickets are required at a nominal cost and may be purchased at the registration desk.

Please plan to enjoy an unforgettable experience in one of Egypt’s historical sites, while savoring an Egyptian dinner, entertainment and oriental atmosphere.

**Speakers’ Preview Room – Akhnaton B**
Speakers are asked to hand in their formatted files (PowerPoint presentations) at the Speaker Ready Room at least two hours before their session. All conference rooms contain state-of-the-art technical equipment. Audiovisual material will be available for your presentation:

**The Speakers’ Preview Room will be open as follows:**

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>22 May</td>
<td>07:00 to 17:00</td>
</tr>
<tr>
<td>Sunday</td>
<td>23 May</td>
<td>07:00 to 17:00</td>
</tr>
<tr>
<td>Monday</td>
<td>24 May</td>
<td>07:00 to 17:00</td>
</tr>
<tr>
<td>Tuesday</td>
<td>25 May</td>
<td>07:00 to 13:00</td>
</tr>
</tbody>
</table>

All presenters, please refer to page 23 for details.

**Tipping**
While tipping is not essential, people who provide a service, like hotel porters, waiters, drivers and guides, generally expect a gratuity. There is no set amount of tip, although 10% as a guideline is recommended.
**General Information** (Continued)

**Webcast & Podcast (New!)**

ISTH is launching a new project this year in providing the Educational Sessions as online webcasts so that you may revisit them once you return home. ISTH members and registered delegates will be directly e-mailed with details on how to access the webcasted sessions as they become available a few weeks following the meeting.

Enjoy fully animated multimedia presentations including laser pointer movements done by the speaker and embedded videos when available. You will also be able to download the PowerPoint slides if shared by the speaker and download the presentations as video podcasts for offline viewing on your video iPod or iPhone device!

**Cairo**

Cairo is alive and awake 24/7. Monuments of history, like pyramids and minarets, or a colossus of almost every civilization can be visited by day. Evenings can be spent in Parisian style streets, the oriental bazaar and the ultra modern megamalls with shops, cafes & restaurant offering food and drink from every corner of the word, especially Kebab, falafel & an Egyptian-made glass of tea with mint.

Cairo is not just a city but an encyclopedia of past, present & future.
Guidelines and Information for Chairmen and Speakers

Speakers are asked to give their formatted files (PowerPoint presentations) to the Speakers’ Preview Room at least two hours before their session. All conference rooms contain state-of-the-art technical equipment. Audiovisual support will be available for your presentation:

**Single Power Point projection only (PC compatible, mandatory)**

We kindly draw your attention to the fact that only a single PowerPoint projector will be available. Personal laptop computers will not be accepted for presentations, as all presentations will be distributed from a central location.

We strongly recommend that you bring a copy of your presentation with you, either on a CD-Rom or USB Memory Stick, as a backup. The organizers will not be held responsible for missing presentations or corrupted files.

Speakers will have the opportunity to check or make amendments to their PowerPoint presentations the day before their scheduled talk.

**The Speakers’ Preview Room will be open as follows:**

- Saturday, 22 May 07:00 to 17:00
- Sunday, 23 May 07:00 to 17:00
- Monday, 24 May 07:00 to 17:00
- Tuesday, 25 May 07:00 to 13:00

**PowerPoint**

The Speakers’ Preview Room and the conference rooms will be fully equipped with computers compatible with Microsoft Power Point software only.

**Computers will be equipped as follows:**

- PC computer *(your presentation must be compatible with this configuration)*
- Microsoft Windows XP or more updated versions
- Microsoft Office 2003 or more updated versions
Test your knowledge of NovoSeven® at the Novo Nordisk booth

Visit the Novo Nordisk booth to learn more about NovoSeven® and see what else is on the horizon.

NovoSeven® is a registered trademark owned by Novo Nordisk Health Care AG. APROM ID: 1803. Approved date: March 2010. Novo Nordisk Egypt, 22 Kamal El Din Hussein Street, Sheraton Heliopolis, Cairo, Egypt.
### Program at a Glance

**Saturday, May 22, 2010**

<table>
<thead>
<tr>
<th>Time</th>
<th>Farhaty</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td>Venous Thrombosis 1</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td>Hereditary Bleeding Disorders</td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td><strong>Presidential Plenary</strong></td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td><strong>Lunch and Debate</strong></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td>Inhibitor Development and Choice for Plasma vs Recombinant Factor VIII Products</td>
</tr>
<tr>
<td>13:15</td>
<td></td>
<td>Abolishing all FFP</td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td>14:15</td>
<td></td>
<td>Venous Thrombosis 2</td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td>Women’s Issues in Thrombosis and Hemostasis</td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td>Laboratory Quality Management in Limited Health Resourced Countries</td>
</tr>
<tr>
<td>16:15</td>
<td></td>
<td>Specific Issues in Countries With Limited Health Resources</td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td><strong>Special Symposium</strong></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>Supported by sanofi aventis</td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td>Future Directions in VWD, Hemophilia and Other Bleeding Disorders</td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td>Supported by Baxter</td>
</tr>
<tr>
<td>19:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Program at a Glance

**Sunday, May 23, 2010**

<table>
<thead>
<tr>
<th>Farhaty</th>
<th>Auditorium</th>
<th>Laylaty</th>
<th>L’Auberge Du Nil</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong></td>
<td>Meet the Experts</td>
<td>Meet the Experts</td>
<td></td>
</tr>
<tr>
<td><strong>B</strong></td>
<td><strong>Education Session</strong></td>
<td><strong>Education Session</strong></td>
<td></td>
</tr>
<tr>
<td><strong>C</strong></td>
<td>Antithrombotic Therapy</td>
<td>ITP</td>
<td></td>
</tr>
<tr>
<td><strong>D</strong></td>
<td><strong>Education Session</strong></td>
<td><strong>Education Session</strong></td>
<td></td>
</tr>
<tr>
<td><strong>E</strong></td>
<td>Arterial Disease and Platelet Therapy</td>
<td>Interactive Discussion of Case Histories</td>
<td></td>
</tr>
<tr>
<td><strong>F</strong></td>
<td><strong>Satellite Symposia</strong></td>
<td><strong>Satellite Symposia</strong></td>
<td></td>
</tr>
<tr>
<td><strong>G</strong></td>
<td>Recombinant Therapy for the Management of Haemophilia: Experience from Clinical Practice</td>
<td>VTE Recurrence ... Why Accept This?</td>
<td></td>
</tr>
<tr>
<td><strong>H</strong></td>
<td>Supported by Pfizer</td>
<td>Supported by Bayer Healthcare</td>
<td></td>
</tr>
<tr>
<td><strong>I</strong></td>
<td>Subcommitteee Session</td>
<td>Subcommitteee Session</td>
<td>Subcommitteee Session</td>
</tr>
<tr>
<td><strong>J</strong></td>
<td>Plasma Coagulation Inhibitors</td>
<td>Control of Anticoagulation, Session I</td>
<td>Vascular Biology</td>
</tr>
<tr>
<td><strong>K</strong></td>
<td>von Willebrand Factor, Session I</td>
<td>Fibrinolysis</td>
<td></td>
</tr>
<tr>
<td><strong>L</strong></td>
<td>Egyptian Night Reception</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Meeting Details**

- **Meet the Experts**
  - Hemostasis & Liver Disease
  - Pediatric Thrombosis
- **Education Session**
  - Antiphospholipid Syndrome
  - ITP
  - Interactive Discussion of Case Histories
- **Satellite Symposia**
  - Recombinant Therapy for the Management of Haemophilia: Experience from Clinical Practice
  - VTE Recurrence ... Why Accept This?
  - The Role of LMWHs Beyond Anticoagulation
  - Supported by Pfizer, Bayer Healthcare, Leo Pharma

**Time Slots**

- 08:00 - 22:00

**Program Highlights**

- **Meet the Experts**
  - Farhaty
  - A
  - B
  - C
- **Education Session**
  - Laylaty
  - Auditorium
  - L’Auberge Du Nil
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Farhaty A</td>
<td>Subcommittee Session Disseminated Intravascular Coagulation (DIC)</td>
</tr>
<tr>
<td>09:30</td>
<td>Farhaty B</td>
<td>Subcommittee Session Control of Anticoagulation, Session 2</td>
</tr>
<tr>
<td>10:00</td>
<td>Auditorium</td>
<td>Subcommittee Session von Willebrand Factor, Session 2</td>
</tr>
<tr>
<td>10:30</td>
<td>Laylaty</td>
<td>Subcommittee Session Predictive Variables in Cardiovascular Disease</td>
</tr>
<tr>
<td>11:00</td>
<td>L'Auberge Du Nil</td>
<td>Subcommittee Session Animal, Cellular and Molecular Models of Thrombosis</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td>Satellite Symposium From Disease to Diagnostics</td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td>Supported by Novo Nordisk</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Council Meeting</td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Farhaty A</td>
<td>Auditorium</td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>------------</td>
</tr>
<tr>
<td>07:15</td>
<td><strong>Technical Session</strong>&lt;br&gt;Standardization of Thrombin Generation and First Clinical Applications</td>
<td>(Meeting)</td>
</tr>
<tr>
<td>07:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>07:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>08:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>08:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>08:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>08:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>09:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>09:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>09:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>09:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>10:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>10:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>10:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>10:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>11:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>11:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>11:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>11:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>12:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>12:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>12:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>12:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>13:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>13:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>13:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>13:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>14:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>14:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>14:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>14:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>15:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>15:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>15:30</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>15:45</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>16:00</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
<tr>
<td>16:15</td>
<td>(Subcommittee)</td>
<td>(Session)</td>
</tr>
</tbody>
</table>
Educational Sessions

Educational Session 09:00–10:30

Venous thrombosis 1
Chairmen: Mike Greaves, UK; Amr Gad, Egypt

- The central role of protein S in regulation of coagulation. Tilman Hackeng, The Netherlands
- What is the benefit of testing for heritable thrombophilia? Trevor Baglin, UK
- Prevention of VTE in the hospitalised patient: the evidence. Mike Greaves, UK

Hereditary bleeding disorders
Chairmen: Alok Srivastava, India; Amal El Beshlawy, Egypt

- Hemophilia. The Pia Glas-Greenwalt Memorial Lecture. Alok Srivastava, India
- Rare bleeding disorders. Flora Peyvandi, Italy
- Von Willebrand Disease. William Nichols, USA

Presidential Plenary 11:00–12:30
Chairman: Nevine Kassim, Egypt

- Current views on cause of first and recurrent venous thrombosis. Frits Rosendaal, The Netherlands
- New antiplatelet agents. Marco Cattaneo, Italy

Lunch and Debate Sessions 12:30–14:15

- Inhibitor development and choice for plasma vs recombinant factor VIII products. Anske van der Bom, The Netherlands and Johannes Oldenburg, Germany
- Abolishing all FFP. Trevor Baglin, UK
Educational Sessions (Continued)  Saturday, May 22, 2010

Educational Session  14:30–16:00

Venous thrombosis 2
Chairmen: Sam Schulman, Canada; Sherif El Shalkany, Egypt
- Diagnosis, management & duration of therapy in thrombotic disorders. Henri Bounameaux, Switzerland
- Management of vitamin K antagonists. Felix van der Meer, The Netherlands
- New issues in oral anticoagulation. Sam Schulman, Canada

Women’s Issues
Chairmen: Flora Peyvandi, Italy; Andra James, USA
- The thrombotic risk associated with oral contraceptive use. Astrid Van Hylckama, The Netherlands
- The risk of recurrence of thrombotic thrombocytopenic purpura in congenital and acquired AD13 deficient women. Flora Peyvandi, Italy
- Management of pregnancy in women affected with coagulation disorders. Rezan Kadir, UK

Educational Session  16:30–18:00

Laboratory Quality Management in limited health resourced countries
Chairmen: Steve Kitchen, UK; Francis E Preston, UK
- Preanalytical variables in haemostasis testing. Steve Kitchen, UK
- EQA in low resourced countries. Alok Srivastava, India
- Quality management in haemostasis. John Olson, USA

Specific issues in countries with limited health resources
Chairmen: Tareef Hamza Sallam, Egypt; Naguib Zoheir, Egypt
- Use of laboratory tests to approach a diagnosis in thrombosis & hemostasis. The Marion Barnhart Memorial Lecture. Raul Altman, Argentina
- Safe replacement therapy. Magdy El Ekiaby, Egypt
- How to build up scientific thinking in developing countries. The Shirley Johnson Memorial Lecture. Emin Kansu, Turkey
Meet the Expert Session 08:00–08:45
- Hemostasis & liver disease. Cheng-Hock Toh, UK
- Pediatric thrombosis. Guy Young, USA

Educational Session 09:00–10:30
Antiphospholipid syndrome
Chairmen: Ph G de Groot, The Netherlands; Mohamed Momtaz, Egypt
- The serological criteria that determine the presence of APS. Armando Tripodi, Italy
- How do antiphospholipid antibodies increase the risk of thrombosis and fetal loss? Ph G. de Groot, The Netherlands
- How I treat APS. Vittorio Pengo, Italy

Idiopathic Thrombocytopenic Purpura (ITP)
Chairmen: Andreas Greinacher, Germany; Mohsen El Alfy, Egypt
- Pathogenesis of ITP. Douglas Cines, USA
- Acute ITP and management of acute major bleeding in ITP. Betrand Godeau, France
- Chronic ITP with a special focus on virus infection associated ITP. Howard Liebman, USA

Educational Session 11:00–12:30
Arterial disease and platelet therapy
Chairmen: Alan Nurden, France; Mohamed Ali Taher, Egypt
- Do we need to monitor patients on treatment with clopidogrel? Marco Cattaneo, Italy
- Ticagrelor: PLATO and beyond. Robert Storey, UK
- Thrombocytopenia in a cardiovascular disease setting. Alan Nurden, France

Interactive discussion of case histories
Chairmen: Hadi Goubran, Egypt; Pier Mannucci, Italy; Robert Montgomery, USA
Subcommittee Sessions – Overview

Sunday, May 23, 2010

SSC Session 14:30–18:30
Von Willebrand Factor, Session 1
Plasma Coagulation Inhibitors
Control of Anticoagulation, Session 1
Vascular Biology
Fibrinolysis

Auditorium
Farhaty A
Farhaty B + C
Laylaty
L’Auberge Du Nil

Monday, May 24, 2010

SSC Session 09:00–13:00
Von Willebrand Factor, Session 2
Disseminated Intravascular Coagulation
Control of Anticoagulation, Session 2
Predictive Variables in Cardiovascular Disease
Animal, Cellular and Molecular Models of Thrombosis

Auditorium
Farhaty A
Farhaty B + C
Laylaty
L’Auberge Du Nil

SSC Session 15:00–19:00
Factor VIII and IX, Session 1
Women’s Health Issues in Thrombosis
Lupus Anticoagulant/Phospholipid-dependent Antibodies
Platelet Physiology
Biorheology

Auditorium
Farhaty A
L’Auberge Du Nil
Farhaty C
Laylaty

Tuesday, May 25, 2010

SSC Session 09:00–13:00
Factor VIII and IX, Session 2
Perinatal/Pediatric Hemostasis
Hemostasis and Malignancy
Platelet Immunology
Factor XIII and Fibrinogen
Plasma Kallikrein-Kinin System

Auditorium
Farhaty A
Farhaty B
Farhaty C
Laylaty
L’Auberge Du Nil
## Control of Anticoagulation, Session 1

**Chairman:** Trevor Baglin (UK)

**Co-Chairmen:** Walter Ageno (IT), Job Harenberg (DE), Clive Kearon (CA), John Olson (US), Gualtiero Palareti (IT), Sam Schulman (CA), Antonius Van Den Besselaar (NL)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Revision of WHO Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy</td>
<td>Ton Van Den Besselaar (NL)</td>
</tr>
<tr>
<td>14:50</td>
<td>REGISTRY: Recurrent venous thromboembolism in anticoagulated patients with cancer</td>
<td>Sam Schulman (CA)</td>
</tr>
<tr>
<td>15:00</td>
<td>Reporting Prothrombin Time Results as International Normalised Ratios for Patients with Chronic Liver Disease</td>
<td>Armando Tripodi (IT)</td>
</tr>
<tr>
<td>15:30</td>
<td>UK NEQAS Anticoagulant dosing exercise</td>
<td>Ian Jennings (UK)</td>
</tr>
<tr>
<td>15:50</td>
<td>Intra-individual variation of INR and analytical quality requirements</td>
<td>Ton Van Den Besselaar (NL)</td>
</tr>
<tr>
<td>16:10</td>
<td>The influence of the direct fXa inhibitor rivaroxaban on thrombin generation assays in patients with thrombophilia</td>
<td>Thomas Siegemund (USA)</td>
</tr>
<tr>
<td>16:20</td>
<td>Thromboprophylaxis after knee arthroscopy and lower leg immobilization with LMWH — monitoring and endpoints</td>
<td>Suzanne Cannegieter (NL)</td>
</tr>
<tr>
<td>16:40</td>
<td>Rivaroxaban and apixaban — age, weight, gender and renal function on rivaroxaban pharmacokinetics</td>
<td>Michael Rud Lassen (DK)</td>
</tr>
<tr>
<td>17:10</td>
<td>A working party to delineate methodology/endpoints/harmonization of present and future studies on perioperative AC management and bridging therapy</td>
<td>Alex Spyropoulos (CA)</td>
</tr>
</tbody>
</table>
Subcommittee Sessions (Continued)  Sunday, May 23, 2010

SSC Session  L’Auberge Du Nil  14:30–18:30

Fibrinolysis

Chairman: Colin Longstaff (UK)
Co-chairmen: Carl-Erik Dempfle (DE), Ann Gils (BE), Dirk Hendriks (BE), Osamu Matsuo (JP), Michael Nesheim (CA), Tetsumei Urano (JP)

WHO International Standards

- The WHO 2nd International Standard for Streptodornase  14:30
  Calibration of tPA antigen in the SSC/ISTH secondary plasma standard lot 3 and lot 4? Update on standardising PAI-1 antigen measurements in plasma. Colin Longstaff (UK)

- Program to replace the WHO International Standard for Urokinase and other serine proteases  14:45
  Craig Thelwell (UK)

TAFI/CPU

- PAI-1 and TAFI measurements on samples from inflammatory bowel disease patients  15:00
  Ann Gils (BE)

- Applying functional TAFIa (CPU) assays to samples from hemophiliacs  15:20
  Michael Nesheim (CA)

- Comparative study on proCPU/TAFI assays  15:40
  Evelien Heylen & Dirk Hendriks (BE)

Coffee break

Methods

- Global Fibrinolysis Assays  16:20
  Tetsu Urano (JP)

- Comparison of methods used to study Fibrinolysis  16:40
  Nicola Mutch (UK)

D-dimer

- Update on the NEQAS EQA for D-dimer  17:00
  Ian Jennings (UK)

- Production and analysis of fibrin degradation products  17:15
  Michael Nesheim (CA)

- Plans for a collaborative study to prepare a reference preparation for D-dimer  17:35
  Steve Kitchen (UK)

AOB, General discussion  17:50
Plasma Coagulation Inhibitors

Chairman: Herbert C Whinna (US)

Co-chairmen: Francesco Bernardi (IT), Elaine Gray (UK), Tilman Hackeng (NL), Steven Kitchen (UK), Richard Marlar (US), P Meijer (NL), Laurent Mosnier (US)

- Inconsistencies in protein C assay sensitivity to protein C defects
  Peter Cooper (UK)

- Variation in protein S activity measurement in clinical samples between different methods
  Ian Jennings (UK)

- Collaborative study on the establishment of the 3rd International Standard for Antithrombin, Plasma
  Elaine Gray (UK)

- Availability of reference plasmas for thrombin generation tests
  Elaine Gray (UK)

- Report from Working Party on Thrombin Generation Tests
Subcommittee Sessions (Continued)  Sunday, May 23, 2010

SSC Session  Laylaty  14:30–18:30

Vascular Biology
Chairman: Françoise Dignat George (FR)
Co-chairmen: Michael Berndt (IE), Jean-Marie Freyssinet (FR), John Griffin (US), Peter Newman (US)

Shed proteins/receptors
Chairmen: Michael Berndt (IE), Peter J Newman (US)
- Basic mechanisms regulating receptor shedding  14:30
  Robert Andrews (AU)
- Soluble GPVI as a clinical biomarker  14:50
  Michael Berndt (IE)
- Soluble CD146 displays angiogenic properties in vivo  15:10
  Nathalie Bardin (FR)

Characterization of circulating endothelial cells and progenitors
Chairmen: Françoise Dignat-George (FR), John Griffin (US)
- Application of Polychromatic Flow Cytometry to Identify Circulating Mature Endothelial and Endothelial Progenitor Cells with Colony Forming Potential  15:30
  Jamie Case (US)
- Limits and advantages of direct flow cytometry for circulating endothelial cell detection  15:50
  Françoise Farrace (FR)
- Multifaceted circulating endothelial cells  16:10
  Patrizia Mancuso (IT)

(Continues)
Vascular Biology (Continued)

Determination and characterization of (circulating) microparticles

Chairmen: Jean-Marie Freyssinet (FR), Nigel Key (US)

- Pre-analytical variables for plasma MP TF activity determination
  Nigel Key (US)  
  16:30

- Analysis of pre-analytical variables for circulating MP enumeration by flow cytometry
  Romaric Lacroix (FR)  
  16:50

- Advances in nanocytometry
  Chris Gardiner (UK)  
  17:10

- A survey of last generation FCM performances
  Bernard Chatelain (BE)  
  17:30

- Advances in impedance-based Flow Cytometry
  Bruce Furie or Jeff Zwicher (US)  
  17:50

- Correlation between capture assay and flow cytometry in microparticle determination
  Jean-Marie Freyssinet, Françoise Dignat-George (FR)  
  18:10
Von Willebrand Factor

Chairman: Jeroen Eikenboom (NL)
Co-chairmen: Thomas Abshire (US), Imre Bodo (HU), Giancarlo Castaman (IT), Jorge DiPaola (US), Emmanuel J Favaloro (AU), Anne Goodeve (UK), Bernhard Lämmle (CH), David Lillicrap (CA), Reinhard Schneppenheim (DE)

Standardized Bleeding Scores. Joint session with the following subcommittees:

— Perinatal/Pediatric Hemostasis
— Factor VIII & Factor IX
— Women’s Health Issues in Thrombosis and Haemostasis
— Platelet Physiology

Chairmen: Thomas Abshire (USA)/David Lillicrap (CA)

- Introduction 14:30
  Francesco Rodeghiero (IT)
- Bleeding scores: adult 14:35
  Alberto Tosetto (IT)
- Bleeding score: pediatric 14:50
  Margaret Rand (CA)
- Bleeding scores: rare bleeding disorders 15:10
  Flora Peyvandi (IT)
- Bleeding scores: women’s health 15:30
  Andra James (US)
- Working party for standardized bleeding score: “new” bleeding assessment tool 15:50
  Francesco Rodeghiero (IT)

Discussion 16:10

Coffee break
Von Willebrand Factor (Continued)

VWF assays for VWD diagnosis

Chairman: Reinhard Schneppenheim (DE)

- Alternative assays for GPIb binding, update
  Hans Deckmy (BE) 16:50
  Bob Montgomery (US) 17:00
  Reinhard Schneppenheim (DE) 17:10

- Collagen binding assay, current status
  Jeroen Eikenboom (NL), on behalf Emmanuel Favaloro (AU) 17:20

- Flow based assays
  Jaap-Jan Zwaginga (NL) 17:30
  Keith Neeves (US) 17:40

Discussion 17:50

VWF propeptide studies

Chairman: Anne Goodeve (UK)

- Working party on standardization of VWFpp assays 18:00
  Tony Hubbard (UK)

Discussion 18:10

VWF plasma and concentrate standards

Chairman: Giancarlo Castaman (IT)

- WHO 2nd International Standard for VWF concentrate 18:20
  Tony Hubbard (UK)
Subcommittee Sessions (Continued)  Monday, May 24, 2010

SSC Session L’Auberge Du Nil 09:00–13:00

Animal Models

Chairman: Timothy Nichols (US)
Co-chairmen: Edward Conway (CA), Shaun Coughlin (US), Jay Degen (US), Nigel Mackman (US), Eva-Maria Muchitsch (AT), Susan Smyth (US), Hugo Ten Cate (NL), Hartmut Weiler (US)

- **Standardization of the Murine Tail Bleeding Model**  09:00
  - This short manuscript will be submitted soon.
  Eva-Maria Muchitsch (AT)
- **Models of clotting in Murine Atherosclerosis**  09:30
  Hugo ten Cate (NL)
- **Mouse Models of von Willebrand Disease**  10:00
  David Lillicrap (CA)
- **Sensitivity of the Whole Blood Clotting Time to F.IX in Canine hemophilia B** – will present this project as a candidate for the short manuscript.  10:30
  Tim Nichols (US)
- **Ferric chloride arterial thrombosis standardization**  11:00
  Tim Nichols (US) on behalf of Nigel Mackman
- **Plans for Animal Models Subcommittee Meeting**  11:15
  at XXIII ISTH Congress, 2011, Kyoto Japan
**Subcommittee Sessions** (Continued)  **Monday, May 24, 2010**

**SSC Session**  **Farhaty B+C**  **09:00–13:00**

**Control of Anticoagulation, Session 2**

**Chairman:** Trevor Baglin (UK)

**Co-chairmen:** Walter Ageno (IT), Job Harenberg (DE), Clive Kearon (CA), John Olson (US), Gualtiero Palareti (IT), Sam Schulman (CA), Antonius Van Den Besselaar (NL)

- Update on the development of generic low molecular weight heparins and adherence to recommendations of scientific organizations
  Jawed Fareed (US)

- Report of the working party on standardization of methods to determine direct factor Xa inhibitors
  Job Harenberg (DE)

- Differential Effects of Various Anticoagulants as measured by Thromboelastography
  Guy Young (US)

- Thrombin generation in orthopaedic patients receiving rivaroxaban
  Sam Machin (UK)

**Discussion and Summary**

**Coffee break**

**Long term control of anticoagulation in patients with thrombosis in unusual sites**

- Splanchnic vein thrombosis registry  Walter Ageno (IT)
- Thrombosis in unusual sites, recent activities and potential perspectives  Francesco Dentali (IT)
- New prospective data on CVT and OAT  Ida Martinelli (IT)

**New oral Anticoagulants** – Round table discussion including:

- status of clinical trials
- information to patients
- assessing compliance

- laboratory tests
- phase IV studies

**Planning of future Subcommittee activities**

10:20

10:00

11:00

12:00

12:45
### Subcommittee Sessions (Continued)  Monday, May 24, 2010

**SSC Session**  Farhaty A  09:00–13:00  

**DIC**

**Chairman:** Hideo Wada (JP)  
**Co-chairmen:** Hyun Kyung Kim (KR), Jorn Dalsgaard Nielsen (DK), Jecko Thachil (UK), Cheng-Hock Toh (UK)

**Diagnosis and Treatment**

- **Chairman’s report**  09:00
- **British Society for Standards in Hematology**  
  **Guideline in DIC**  
  Cheng-Hock Toh (UK)
- **Japanese guideline on DIC**  
  Hideo Wada (JP)  09:30

**Discussion**  09:45

**Educational session** (80 min)

- **Pathogenetic role of alarmin, HMGB1 in DIC**  
  Ikuro Maruyama (JP)  09:50
- **Pathophysiological consideration in sepsis-induced DIC**  
  Jecko Thachil (UK)  10:20
- **DIC due to tropical disease**  
  Pantep Angchaisuksiri (TH)  10:35

**Discussion**  10:55

*Coffee break*
DIC (Continued)

**Standardization issues** (100 min)

- **Considerations on the use of the ISTH non-overt DIC scoring system** 11:15
  Jorn Dalsgaard Nielsen (DK)

- **Evaluation of modified non-overt DIC criteria on the prediction of the poor-outcome in patients with sepsis** 11:35
  Doyeun Oh (KR)

- **Effect of cardiopulmonary bypass on activated partial thromboplastin time waveform analysis, serum procalcitonin and C-reactive protein concentrations** 11:55
  Maxime Cannesson (FR)

- **Working group on Clt WF analysis** 12:15
  Jecko Thachil (UK)

- **Accuracy of platelet counting by the automated hematologic analyzers disseminated intravascular coagulation: potential effects of platelet activation on the platelet measurement** 12:25
  Hyun Kyung Kim (KR)

- **Prospective study in Japan** 12:45
  Hideo Wada (JP)

Discussion 12:55
**Subcommittee Sessions** (Continued)  Monday, May 24, 2010

**SSC Session**  Laylaty  **09:00–13:00**

**Predictive Variables in Cardiovascular Disease**

**Chairman:** James Douketis (CA)

**Co-chairmen:** Gordon Lowe (UK), Frederick Spencer (CA), Alberto Tosetto (IT), Richard White (USA)

**Part A: Update of Subcommittee-related Activities**
(15 min presentations + 5 min QA)

- **Factor IX Malmö and recurrent VTE**  09:00
  Willem Lijfering (NL)

- **MicroRNA and venous thrombosis**  09:20
  Carla Vossen (NL)

- **D-dimer and Recurrent VTE Collaborative Group**  09:40
  Campbell Tait (UK)

- **New molecular markers of CV disease**  10:00
  Sue He and Margareta Blombäck (SE)

- **Global tests to predict VTE**  10:20
  Astrid van Hylckama Vlieg (NL)

- **Residual vein thrombosis and recurrent thrombosis**  10:40
  Walter Ageno (IT)

*Coffee break*

**Part B: Educational Session** (20 min presentations + 5 min QA) and Debate (15 min presentations + 5 min rebuttals x 2)

- **Established CV risk factors**  11:20
  Mary Cushman (US)

- **New and emerging CV risk factors**  11:45
  Moniek de Maat (NL)

- **Should CRP be used in everyday practice to risk-stratify patients without established CV disease? Yes**  12:10
  Mary Cushman (US)

- **Should CRP be used in everyday practice to risk-stratify patients without established CV disease? No**  12:30
  Moniek de Maat (NL)
### Von Willebrand Factor, Session 2

**Chairman:** Jeroen Eikenboom (NL)

**Co-chairmen:** Thomas Abshire (US), Imre Bodo (HU), Giancarlo Castaman (IT), Jorge DiPaola (US), Emmanuel J Favaloro (AU), Anne Goodeve (UK), Bernhard Lämmle (CH), David Lillicrap (CA), Reinhard Schneppenheim (DE)

#### ADAMTS13

**Chairman:** Thomas Abshire (US)

- **Fluorogenic and chromogenic assays of ADAMTS13 activity** 09:00
  Koichi Kokame (JP)/ Yoshihiro Fujimura (JP)
- **VWF and ADAMTS13 interactions** 09:15
  Reinhard Schneppenheim (GE)

**Discussion** 09:30

#### VWF and VWD registries

**Chairman:** Imre Bodo (HU)

- **Platelet Type – VWD registry** 09:40
  Maha Othman (CA)
- **VWF Mutation database** 10:00
- **Need for a steering committee**
- **Publication/report on database**
  Anne Goodeve (UK)/Dan Hampshire (UK)

**Discussion** 10:20

*Coffee break*
Subcommittee Sessions (Continued)  Monday, May 24, 2010

SSC Session  Auditorium  09:00–13:00

Von Willebrand Factor, Session 2 (Continued)

Maintenance of websites of different Working Parties  10:50

Chairman:  David Lillicrap (CA)

- www.ddavp-in-vwd.com
  Working party on desmopressin in the management of VWD
- www.intreavws.com
  International registry on acquired VWD
- www.vwfassays-in-vwd.com
  Working party on VWF assays in VWD diagnosis
  Augusto Federici (IT)

Discussion  11:00

Ongoing and starting multicenter studies on VWD

Chairman:  Jorge DiPaola (USA)/Jeroen Eikenboom (NL)

- Working party on desmopressin in the management of VWD  11:10
  Publication/report  Augusto Federici (IT)
- Working party on VWF assays in VWD diagnosis  11:20
  Publication/report  Carlo Castaman (IT)
- European Project on type 3 VWD  11:30
  Augusto Federici (IT)
- EU VWD Cooperative Group  11:45
  Ian Peake (UK)
- Zimmerman Project (ZPMCB-VWD)  12:00
  Bob Montgomery (USA)
- GWAS on VWD/bleeding phenotype  12:10
  Jorge DiPaola (USA)
- VWD International Prophylaxis (VIP) Study  12:20
  Tom Abshire (USA)
- WIN (Willebrand in Netherlands)  12:35
  Jeroen Eikenboom (NL)

Discussion  12:50
**Subcommittee Sessions** (Continued)  **Monday, May 24, 2010**

**SSC Session**  **Laylaty**  **15:00–19:00**

**Biorheology**

**Chairman:** Johan Heemskerk (NL)

**Co-chairmen:** Lawrence Brass (US), Thomas Diacovo (US), Shaun Jackson (AU), Mike King (US), Armin Reininger (DE), Jaap-Jan Zwaginga (NL)

**Session 1. Thrombus formation: novel methods and standardization**

**Chairmen:** Armin Reininger (DE), Thomas Diacovo (US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Towards standardization of biorheological assays – opening remarks</td>
<td>Johan Heemskerk (NL)</td>
</tr>
<tr>
<td>15:10</td>
<td>Time-resolved measurement of thrombus formation on a microfluid biochip</td>
<td>Chris Jones (UK)</td>
</tr>
<tr>
<td>15:30</td>
<td>Use and potential for flow devices in measurement of thrombus formation</td>
<td>Mark Roest (NL)</td>
</tr>
<tr>
<td>15:50</td>
<td>Microfluidic high throughput assays of platelet adhesion</td>
<td>Keith Neeves (US)</td>
</tr>
<tr>
<td>16:10</td>
<td>Fibrin formation and thrombus stability under flow</td>
<td>Armin Reininger (DE)</td>
</tr>
<tr>
<td>16:30</td>
<td>Possibilities and limitations in the standardization of in vivo thrombosis studies in mouse</td>
<td>Cecile Denis (FR)</td>
</tr>
</tbody>
</table>

*Coffee break*

(Continues)
### Biorheology (Continued)

#### Session 2. Blood flow-dependent processes *in vitro* and *in vivo*: novel concepts

**Chairmen:** Mike King (US), Johan Heemskerk (NL)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:10</td>
<td>Lessons learned from the measurement of platelet adhesion receptor kinetics</td>
<td>Mike King (US)</td>
</tr>
<tr>
<td>17:30</td>
<td>Platelet adhesion kinetics: from mathematical modeling to <em>in vivo</em> relevance</td>
<td>Thomas Diacovo (US)</td>
</tr>
<tr>
<td>17:50</td>
<td>Microfluidic assays to study local disturbances in blood rheology on platelet adhesion and aggregation</td>
<td>W. Nesbitt (AU)</td>
</tr>
<tr>
<td>18:10</td>
<td>Thrombus formation and plaques <em>in vivo</em> and <em>in vitro</em></td>
<td>Marýke Kuijpers (NL)</td>
</tr>
<tr>
<td>18:30</td>
<td>Role of ADAMTS13 in flow-dependent thrombus formation</td>
<td>Mitsuhiko Sugimoto (JP)</td>
</tr>
<tr>
<td>18:50</td>
<td>Final discussion and closing remarks</td>
<td>Johan Heemskerk (NL)</td>
</tr>
</tbody>
</table>
Subcommittee Sessions (Continued)  Monday, May 24, 2010

SSC Session Auditorium 15:00–19:00

Factor VIII and IX, session 1
Chairman: Alok Srivastava (IN)
Co-chairmen: Jan Asterolmark (SE), Kathelijn Fischer (NL), Charles Hay (UK), Claude Negrier (FR), Johannes Oldenburg (DE), Flora Peyvandi (IT), Edward Tuddenham (UK), Leonard Valentino (US)

- Welcome and Introductions
  Alok Srivastava (IN)
- Completed/Submitted reports and new developments
  Alok Srivastava (IN)

Section I – Rare Bleeding Disorders
Chairmen: Flora Peyvandi (IT) and Edward Tuddenham (UK)

- Overview 15:10
  Flora Peyvandi (IT) and Edward Tuddenham (UK)
- European network of RBDs (EN-RBD): Results of the collaboration at 3 years 15:15
  Flora Peyvandi (IT)
- RBD – the WFH database 15:30
  Paula Bolton-Maggs (UK)
- Bleeding scores in RBD 15:45
  Roberta Palla (IT)
- Evaluation of F XIII deficiency – Available assays and their limitations 16:00
  Laszlo Muszbek (HU)
- Monitoring hemostasis during surgery in FXI deficiency 16:15
  Edward Tuddenham (UK)
- Definitions in rare bleeding disorders – Report of the working group 16:30
  Flora Peyvandi (IT)

General discussion / Future directions 16:50

Coffee break

(Continues)
Subcommittee Sessions (Continued)  Monday, May 24, 2010

SSC Session  Auditorium  15:00–19:00

Factor VIII and IX, session 1 (Continued)

Section II – Factor VIII/IX: Clinical issues – I (Assay/EQA/Phenotype)

Chairmen: Claude Negrier (FR) and Jan Astermark (SE)

- Overview: Tests of global hemostasis and their applications  17:20
  Claude Negrier (FR) and Jan Astermark (SE)
- Towards standardization of TGT –  17:25
  Report of the working party
  Claude Negrier (FR)
- Towards standardization of TEG –  17:45
  Report of the working party
  Benny Sorensen (UK)
- Towards standardization of clot wave form analysis –  18:05
  Report of the working party
  Midori Shima (JP)
- Could global haemostasis tests be used to tailor treatment in hemophilia?  18:25
  Jovan P. Antovic (SE)

General discussion / Future directions  18:45
Subcommittee Sessions (Continued)  Monday, May 24, 2010

SSC Session  L’Auberge Du Nil  15:00–19:00

Lupus Anticoagulants/Phospholipid-dependent Antibodies

Chairman: Thomas L Ortel (US)
Co-chairmen: Ph de Groot (NL), Bas de Laat (NL), Vittorio Pengo (IT), Jacob Rand (US), Guido Reber (CH), Armando Tripodi (IT)

- Updates from the APS Meeting in Galveston  15:00
  Silvia Pierangelli (US), Thomas L. Ortel (US)
- Diagnosis of APS: Proposed Consensus Document  15:25
  Vittorio Pengo (IT)
- Is a single positive test sufficient to diagnose APS?  15:55
  Vittorio Pengo (IT)
- Lupus anticoagulant: an attempt at standardization  16:25
  Armando Tripodi (IT)

Coffee break  16:45

- β2 glycoprotein I conformation and antibody recognition  17:00
  Philip de Groot (NL)
- Human monoclonal antibody standards for antiphospholipid antibody testing  17:30
  Bas de Laat (NL)
- Developing the annexin A5 inhibition assay for clinical laboratory use  17:45
  Jacob Rand (US)

Clinical and Laboratory Issues in APS: Special Populations  18:15
  - Pediatric APS
    Gili Kenet (Israel) and Ulrike Nowak-Göttl (DE)
  - Obstetrical complications and APS
    Andra James (US)
Subcommittee Sessions (Continued)  Monday, May 24, 2010

SSC Session  Farhaty C  15:00–19:00

Platelet Physiology
Chairman: Marco Cattaneo (IT)
Co-chairmen: Christian Gachet (FR), Paolo Gresele (IT), Paul Harrison (UK), Catherine Hayward (CA), Dermot Kenny (IR), Alan Michelson (US), Diane Nugent (US), Stephen Watson (UK)

First Session
Chairmen: Marco Cattaneo (IT), Paolo Gresele (IT)

- Inherited platelet function disorders: an overview  15:00
  C. van Geet (BE)
- Diagnosis of platelet function disorders  15:30
  Andrew Mumford (UK)
- Update on standardized bleeding scores for patients with defects of primary hemostasis  16:00
  Alberto Tosetto (IT)
- Organization of the Working Party on diagnosis of platelet function disorders  16:30

General Discussion
Coffee break  17:00

Second Session
Chairmen: Marco Cattaneo (IT), Christian Gachet (FR)

- Factors influencing the individual response to clopidogrel  17:30
  Robert Storey (UK)
- The use of laboratory tests of platelet function to assess the bleeding risk in patients on treatment with thienopyridines  18:00
  Dirk Sibbing (DE)
- Final report of the Working Party on LTA Standardization  18:30
  Marco Cattaneo (IT), on behalf of the Working Party on LTA Standardization: Chiara Cerletti (IT), Paul Harrison (UK), Catherine PM Hayward (CA), Dermot Kenny (IR), Alan D Michelson (US), Diane Nugent (US), Paquita Nurden (FR), Koneti A Rao (US), Alvin Schmeier (US), Steve Watson (UK)
Women’s Health Issues in Thrombosis and Haemostasis

Chairman: Sabine Eichinger (AT)
Co-chairmen: Margareta Blombäck (SE), Benjamin Brenner (IL), Jacqueline Conard (FR), Andra James (US), Barbara Konkle (US), Peter Kouides (US), Claire McLintock (NZ), Claire Philipp (US)

- Welcome and Introduction of Co-chairmen
  Sabine Eichinger (AT)
- Program Overview

Educational activities

Chairman: Benjamin Brenner (IL)

- Educational Program of Subcommittee Meetings: Overview and future perspectives
  Sabine Eichinger (AT)
  Benjamin Brenner (IL)
- ISTH educational activities for developing countries
  Benjamin Brenner (IL)

Subcommittee initiated projects – part I

Chairman: Andra James (US)

- Type 1 VWD in Pregnancy
  Barbara Konkle (US)
- Diagnosis of deep-vein thrombosis and pulmonary embolism in pregnancy – an update
  Menno V. Huisman (NL)
- Contraception and the risk of venous thromboembolism: Practical considerations in high-risk women
  Jacqueline Conard (FR)

(Continues)
Subcommittee Sessions  (Continued)   Monday, May 24, 2010

SSC Session  Farhaty A  15:00–19:00

Women’s Health Issues in Thrombosis and Haemostasis  (Continued)

Update on Registries
Chairman: Sabine Eichinger (AT)
- Overview of past registries; future perspectives  16:20
  Andra James (US)

Coffee break  16:30

Subcommittee initiated projects – part II
Spotlight on “Thrombophilia and pregnancy outcomes”
Chairman: Claire McLintock (NZ)
- The relevance of thrombophilic risk factors and pregnancy outcomes  16:50
  Claire McLintock (NZ)
- Aspirin and Aspirin Combined with Low-Molecular-Weight Heparin in Women with Unexplained Recurrent Miscarriage: a Randomized Controlled Multicenter Trial (ALIFE Study)  17:15
  Saskia Middeldorp (NL)

Menorrhagia Working Group
Chairman: Claire S. Philipp (US)
- Standardized Bleeding Scores  17:35
  Claire S. Philipp (US)
- The risk of miscarriage in women with rare bleeding disorders  17:50
  Flora Peyvandi (IT)
- More health challenges for women with hereditary bleeding disorders in communities where fertility is essential  18:10
  Magdy El-Ekiaby (EG)

New projects
Chairman: Sabine Eichinger (AT)
- Travel and thrombosis in women  18:30
  Benjamin Brenner (IL)
- Assay of TF and TFPI on microparticles in pregnancy complications  18:40
  Anat Aharon (IL)

Closing Remarks
Chairman and Co-Chairmen  18:50
## Subcommittee Sessions (Continued)  Tuesday, May 25, 2010

<table>
<thead>
<tr>
<th>SSC Session</th>
<th>Auditorium</th>
<th>09:00–13:00</th>
</tr>
</thead>
</table>

**Factor VIII and IX, session 2**

**Chairman:** Alok Srivastava (IN)

**Co-chairmen:** Jan Astermark (SE), Kathelijn Fischer (NL), Charles Hay (UK), Claude Negrier (FR), Johannes Oldenburg (DE), Flora Peyvandi (IT), Edward Tuddenham (UK), Leonard Valentino (US)

**Section III – Factor VIII/IX: Clinical issues-II (Outcomes/Inhibitors)**

**Chairmen:** Charles Hay (UK) and Kathelijn Fischer (NL)

- **Overview**
  - Charles Hay (UK), Kathelijn Fischer (NL)
  - 09:00

- **Definitions in hemophilia – Report of the working party**
  - Victor Blanchette (CA)
  - 09:05

- **Pharmacokinetic evaluation in hemophilia – Report of the working party**
  - Sven Bjorkman (SE), Peter Collins (UK)
  - 09:25

- **International ITI study: Update**
  - Donna DiMichele (US), Charles Hay (UK)
  - 09:45

- **Genetic predictors of inhibitor development – Update of ongoing studies**
  - Jan Astermark (SE)
  - 10:00

- **Regulatory perspective on clinical development of FVIII/FIX concentrates – FDA**
  - Nisha Jain (US)
  - 10:15

- **EU-Regulatory perspective on clinical development of FVIII/FIX concentrates – EMEA**
  - Anneliese Hilger (DE)
  - 10:30

- **General discussion/Future directions**
  - 10:45

*Coffee break*
### Subcommittee Sessions (Continued)  
**Tuesday, May 25, 2010**

#### Factor VIII and IX, session 2 (Continued)

**Section IV – Factor VIII/IX: Products and Standards**

**Chairmen:** Johannes Oldenburg (DE) and Leonard Valentino (US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Overview</td>
</tr>
<tr>
<td></td>
<td>Johannes Oldenburg (DE) and Leonard Valentino (US)</td>
</tr>
<tr>
<td>11:05</td>
<td>New factor concentrates – ‘Biosimilars’or ‘Biosuperiors’:</td>
</tr>
<tr>
<td></td>
<td>How do we evaluate them for clinical use?</td>
</tr>
<tr>
<td></td>
<td>Leonard Valentino (US)</td>
</tr>
<tr>
<td>11:20</td>
<td>Evaluating new factor concentrates – What are the issues?</td>
</tr>
<tr>
<td></td>
<td>Martin Lee (US)</td>
</tr>
<tr>
<td>11:35</td>
<td>Evaluating new factor concentrates –</td>
</tr>
<tr>
<td></td>
<td>Regulatory perspectives: EMEA</td>
</tr>
<tr>
<td></td>
<td>Anneliese Hilger (DE)</td>
</tr>
<tr>
<td>11:50</td>
<td>Regulatory perspectives: FDA</td>
</tr>
<tr>
<td></td>
<td>Mark Weinstein (US)</td>
</tr>
<tr>
<td>12:05</td>
<td>Review of completed and new standardization projects on standards</td>
</tr>
<tr>
<td></td>
<td>Anthony Hubbard (UK)</td>
</tr>
<tr>
<td>12:15</td>
<td>4th International Standard for Blood coagulation</td>
</tr>
<tr>
<td></td>
<td>Factors II, VII, IX and X, Plasma</td>
</tr>
<tr>
<td></td>
<td>Elaine Gray (UK)</td>
</tr>
<tr>
<td>12:25</td>
<td>Factor VIII inhibitor standard: Status update</td>
</tr>
<tr>
<td></td>
<td>Koen Mertens (NL)</td>
</tr>
<tr>
<td>12:35</td>
<td>FVIII field study – Comparison of BDD product with a full length product.</td>
</tr>
<tr>
<td></td>
<td>David Lillicrap (CA)</td>
</tr>
<tr>
<td>12:45</td>
<td>General discussion/Future directions</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>12:55</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td></td>
<td>Alok Srivastava (IN)</td>
</tr>
</tbody>
</table>
Subcommittee Sessions (Continued) Tuesday, May 25, 2010

SSC Session Laylaty 09:00–13:00

Factor XIII and Fibrinogen

Chairman: Hans Kohler (CH)
Co-chairmen: Moniek de Maat (NL), Aida Inbal (IL), Jaap Koopman (NL), Muriel Maurer (US), Leonid Medved (US), Marguerite Neerman-Arbez (CH), John Weisel (US)

Part 1: Fibrinogen

- An update on the replacement of the 2nd International Standard for Fibrinogen, Plasma (98/612) 09:00
  Sanj Raut (UK)
- An update on the replacement of the 1st International Standard for Fibrinogen, Concentrate (98/614) 09:15
  Sanj Raut (UK)
- Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of t-PA and plasminogen to fibrin 09:30
  Nicola J Mutch (UK)
- Update on fibrin structure standardization 09:55
  Marlien Pieters (ZA)
- Molecular mechanisms of fibrin-VE-cadherin interaction and anti-inflammatory properties of fibrin-derived peptides 10:20
  Leonid Medved, Sergiy Yakovlev, Li Zhang (USA)

Coffee break

(Continues)
Factor XIII and Fibrinogen (Continued)

Part 2: Factor XIII

- Challenges of assigning a FXIII-B value to the 1st International FXIII Standard plasma; scientific and methodological considerations
  Muszbek L, Katona É and Bagoly Z (HU) 11:00

- Project of a pilot study to establish the normal value of F13-B concentration using the international standard plasma
  Akitada Ichinose (JP) 11:20

- International survey of acquired hemophilia 13 (Hemorrhagic acquired factor 13 deficiency).
  Proposal for a future international collaborative study
  Akitada Ichinose (JP) 11:40

- Association of FXIII-A with Golgi proteins within monocyte-macrophages
  Paul Cordell (UK) 12:00

- Does MBL-associated serine protease 1 (MASP-1) of the complement system activate factor XIII and induce fibrin formation?
  Verena Schroeder (UK) 12:20

- Pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency
  Diane J Nugent (US) 12:40
Subcommittee Sessions (Continued)  Tuesday, May 25, 2010

SSC Session  Farhaty B  09:00–13:00

Haemostasis and Malignancy
Chairman: Agnes YY Lee (CA)
Co-chairmen: Giancarlo Agnelli (IT), Dominique Farge (FR), Charles Francis (US), Alok Khorana (US), Marina Marchetti (IT), Martin Prins (NL), Wolfram Ruf (US)

Preclinical and Translational studies
Chairmen: Wolfram Ruf (US), Marina Marchetti (IT)

- Tissue factor and intracellular signaling in cancer-associated thrombosis: updates and future direction 09:00
  Wolfram Ruf (US)
- Tissue factor microparticles: roles and relevance in cancer-associated thrombosis 09:30
  Jeffrey Zwicker (US)
- Tissue factor standardization: update of SSC activity 10:00
  Marina Marchetti (IT)

Coffee break 10:30

Clinical Cohorts, Trials and Registries
Chairmen: Alok A Khorana (US), Dominique Farge (FR)

- Prophylaxis in outpatients – time for action? 11:00
  Alok A Khorana (US)
- Prophylaxis in MM – how strong is the evidence? 11:30
  Marc Carrier (CA)
- Incidental thrombosis – to treat or not to treat? 12:00
  Howard Liebman (US)

Ongoing Studies and New Proposals
Chairmen: Agnes Lee (CA), Martin Prins (NL)

- Updates on INPACT, VTE treatment, and others 12:30
  Martin Prins (NL)
- European guidelines for VTE management in cancer 12:45
  Dominique Farge-Bancel (FR)
**Subcommittee Sessions (Continued)  Tuesday, May 25, 2010**

<table>
<thead>
<tr>
<th>SSC Session</th>
<th>Farhaty A</th>
<th>09:00–13:00</th>
</tr>
</thead>
</table>

**Perinatal/Pediatric Hemostasis**

*Chairman:* Paul Monagle (AU)

*Co-chairmen:* Anthony Chan (CA), Janna Journeycake (US), Gili Kenet (IL), Christoph Male (AT), Wolfgang Muntean (AT), Ulrike Nowak-Gottl (DE), Guy Young (US)

- **Introduction** 09:00
  
  Paul Monagle (AU)

**Improving anticoagulant trials in children**

*Chairmen:* Gili Kenet (IL), Ulrike Nowak-Gottl (DE)

- **From adults to neonates: Proposing a standard approach** 09:15
  
  to introducing new anticoagulant drugs in children.
  
  Guy Young (US), Christoph Male (AT)

- **Safety and efficacy endpoints in paediatric anticoagulant** 09:35
  
  trials: Developing an ISTH position paper
  
  Lesley Mitchell (CA)

- **PTS as an outcome measure of paediatric thrombosis** 09:55
  
  therapy: can we develop standardised criteria?
  
  Anthony Chan (CA)

- **Quality of life as outcome measure for anticoagulant trials** 10:15
  
  in children: Developing a standardised tool
  
  Patti Massicotte (CA)

- **Laboratory monitoring of anticoagulants in children:** 10:35
  
  developing a uniform approach
  
  Paul Monagle (AU)

- **Diagnostic criteria for thrombosis in children:** 10:55
  
  Which radiological techniques are validated?
  
  Leo Brandau

**Coffee break** 11:15
## Subcommittee Sessions (Continued)  
**Tuesday, May 25, 2010**

<table>
<thead>
<tr>
<th>SSC Session</th>
<th>Farhaty A</th>
<th>09:00–13:00</th>
</tr>
</thead>
</table>

### Perinatal/Pediatric Hemostasis (Continued)

**Interpretation of laboratory tests in children and clinical bleeding**

**Chairman:** Anthony Chan (CA), Christoph Male (AT)

- **Developmental Haemostasis: Recommendations for laboratories reporting paediatric samples**
  - Gili Kenet (IL)  
  - 11:30

- **Role of thrombophilia testing in children: development of standard indications for testing and assay methodologies**
  - Ulrike Nowak-Gottl (DE)  
  - 11:50

- **Laboratory assessment of bleeding disorders in children: Standardisation protocols**
  - Nicole Schlegel (FR)  
  - 12:10

- **Seven Bleep Registry update**
  - Jan Blatny (CZ), Prasad Mathew (US)  
  - 12:30

**Concluding remarks**

- Paul Monagle (AU)  
  - 12:50
Subcommittee Sessions (Continued)  Tuesday, May 25, 2010

SSC Session Laylaty 09:00–13:00

Factor XI and the plasma contact system (PKKS)
Chairman: Thomas Renne (SE)
Co-chairmen: David Gailani (US), Keith McCrae (US)

- Welcome note 09:00
- Role of factor XII in thrombus formation on collagen 09:05
  Paola van der Meijden (NL)
- Activated factor XII as a risk predictor for cardiovascular disease? 09:30
  Dennis Nielson (NO)
- The plasma Kallikrein-Kinin system and regulation of endothelial progenitor cell function 09:55
  Yi Wu (US)
- Diagnosis and treatment of hereditary angioedema – in 2010 10:20
  Marco Chicardi (IT)
- Presentation of the C1 inhibitor standard 10:45
  Craig Thelwell (UK)

Coffee break

- Role of Factor XII in lung fibrosis 11:15
  Klaus T. Preissner (DE)
- Factor XI activation in vivo 11:40
  Henri Spronk (NL)
- Plasma kallikrein/factor XI structure function relations 12:05
  Jonas Emsley (UK)
- Polyphosphates, novel procoagulant activators 12:30
  Nicola Mutch (UK)
- Concluding remarks, general discussion points 12:55
Subcommittee Sessions (Continued)  Tuesday, May 25, 2010

SSC Session  Farhaty C  09:00–13:00

Platelet Immunology
Chairman: Andreas Greinacher (DE)
Co-chairmen: Donald Arnold (CA), Beng Chong (AU), Yves Gruel (FR), Hartmut Kroll (DE)

- Welcome
  Andreas Greinacher (DE)

Autoimmune thrombocytopenia
Chairman: Donald Arnold (CA)

- Platelet antibody testing in ITP: The need for standardization
  Donald Arnold (CA)

- Are GPIIbIIIa and GPIbIX glycoproteins sufficient for platelet autoantibody testing?
  Hartmut Kroll (DE)

Round table discussion on platelet antibody standardization workshop. Focus on application of platelet antibody tests to clinical studies.

- Discussion topics:
  - The need for direct and indirect testing
  - Sample procurement/ anticoagulant
  - How to prepare shared samples for direct testing (fresh vs. frozen, volume of collection)
  - What antigenic target(s)

(Continues)
Subcommittee Sessions (Continued)  Tuesday, May 25, 2010

SSC Session Farhaty C 09:00–13:00

Platelet Immunology (Continued)

Alloimmune thrombocytopenia

Chairman: Hartmut Kroll (DE)

- Update on platelet alloantigen systems: New approaches in antigen/antibody detection
  Sentot Santoso (DE)
  10:15

- Low affinity platelet alloantibodies, detection and its relevance
  Sentot Santoso (DE)
  10:30

- Prediction of NAIT
  B. Skogen (NO)
  10:45

- genetic pitfalls in platelet genotyping and new platelet antigen(s).
  G. Bertrand, V. Jallu, Cécile Kaplan (FR)
  11:00

- Antenatal management of 81 high risk pregnancies: Maternal immunization and consideration for a less invasive strategy.
  G. Bertand and Cécile Kaplan (FR) for the French working group
  11:15

- Which of the new aspects should be considered for diagnostic approaches and treatment in neonatal alloimmune-thrombocytopenia?
  Hartmut Kroll (DE)
  11:30

Coffee break 11:45

(Continues)
### Subcommittee Sessions (Continued) Tuesday, May 25, 2010

**SSC Session** Farhaty C **09:00–13:00**

**Platelet Immunology (Continued)**

**Heparin-induced thrombocytopenia**

*Chairmen:* Yves Gruel (FR), Andreas Greinacher (DE)

- **How to improve the clinical use of antigen assays in HIT**
  - 12:00
  - B. Tardy

- **Thrombin generation potential in HIT. Does it correlate with clinical manifestation?**
  - 12:00
  - B. Tardy

- **Toward standardization of anti-PF4/heparin antigen assays**
  - 12:15
  - Andreas Greinacher (DE)

- **PF4/polyanion complexes: are there other implications?**
  - 12:30
  - K. Krauel (DE)

- **New data on the performance of PF4/heparin antibody assays**
  - 12:45
Symposia Schedule

Special Symposium Farhaty 18:30–20:30

An evolving VTE management environment: daily practices and new challenges

Chairmen: Sylvia Haas, Germany; Joseph Caprini, USA

- Welcome and Introduction
  Sylvia Haas, Germany
  18:30

Building on experience

- What experience tells us: Clinical cases
  Bernardo Menajovski, USA
  18:35

Experience applied to special populations

- Renal insufficiency
  Sylvia Haas, Germany
  19:00

- Cancer patients
  Alok Khorna, USA
  19:20

What the future holds

- Oral anticoagulants: do we know all on their benefit and safety?
  Joseph Caprini, USA
  19:40

- Biosimilars LMWH ISTH/SSC recommendations: an update
  Job Harenberg, Germany
  20:00

- Closing remarks
  Joseph Caprini, USA
  20:20
**Symposia Schedule**  (Continued)  

**Saturday, May 22, 2010**

**Special Symposium**  
**Auditorium**  
**18:30–20:30**

**Future Directions in VWD, Hemophilia and other Bleeding Disorders**

Chairmen: Wing-Yen Wong, Baxter, USA; David Lillicrap, Canada

- **Introduction**  
  Chair  

  **An evolving treatment paradigm for VWD**  
  18:30

- **Unmet needs in von Willebrand Disease**  
  Jenny Goudemand, France

- **Insights from the biochemical and structural characterization of rVWF**  
  Peter Turecek, Baxter, Austria

- **Update on Baxter’s rVWF clinical program**  
  Tobias Suiter, Baxter, Austria

**Novel pharmaceutical approaches to improving hemostasis**  
19:40

- **TFPI inhibition and non-anticoagulant sulphated polysaccharides (NASP)**  
  Michael Dockal, Baxter, Austria

- **Advances in the understanding of ADAMTS13**  
  Fritz Scheiflinger, Baxter, Austria

- **Q&A and Conclusion**  
  Chair  

  **20:20**
Symposia Schedule (Continued)

Sunday, May 23, 2010

Satellite Symposium

Laylaty 12:45–14:15

The role of LMWHs beyond anticoagulation

Chairman: Prof. Ahmed Saad Eldin, Egypt

- Chairman’s Introduction 12:45
- Long term treatment of DVT with LMWH in post thrombotic syndrome 12:50
  Christos Liapis, Greece
- Key role of LMWH in inflammation and cancer 13:20
  Shaker Mousa, USA
- Discussion 13:50
- Chairman’s closing remarks 14:10
- End of symposium 14:15
### Satellite Symposium Schedule

**Symposia Schedule** (Continued)  
**Sunday, May 23, 2010**

#### Satellite Symposium

**Auditorium**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:45–14:15 | **VTE Recurrence ... why accept this?**  
Chairman: Professor Martin Prins, Netherlands  
- Welcome and Introduction  
- VTE Recurrence ... why accept this? (Keynote talk)  
  Martin Prins, The Netherlands  
- Questions and Answers |
|         | **Recombinant therapy for the management of haemophilia: experience from clinical practice**  
Chairman: Dr. Magdy El Ekiaby, Egypt  
Co-chairman: Prof. Brian Colvin, UK  
- Chairman’s Welcome  
  Dr. Magdy El Ekiaby, Egypt  
- Delivering Optimal Therapy for Haemophilia B: Recombinant FIX – Clinical Evidence and Experience  
  Paul Giangrande, UK  
- Questions and Answers  
- Moroctocog alfa – Clinical Evidence and Experience  
  Alfonso Iorio, Italy  
- Questions and Answers  
- Summary and Close |
Symposia Schedule (Continued)  Monday, May 24, 2010

Satellite Symposium  Farhaty B+C  13:15–14:45

From disease to diagnostics

Chairmen: Magdy El Ekiaby, Egypt; Aida Inbal, Israel
Chairman/Moderator: Johannes Oldenburg, Germany

- Welcome and introduction from the Chairmen
  Magdy El Ekiaby, Egypt; Aida Inbal, Israel
  13:15

- Diagnostics and assays today – a challenge?
  Johannes Oldenburg, Germany
  13:25

- Rare bleeding disorders and aspects of FXIII deficiency
  Flora Peyvandi, Italy
  13:45

- Production and characterisation of recombinant FXIII
  Lene Hørlyck, Novo Nordisk, Denmark
  13:45

- State-of-the-art production of a new recombinant FVIII (N8)
  Knud Vad, Novo Nordisk, Denmark
  14:00

- Novo Nordisk recombinant FVIII – pharmacokinetic study data
  Uriel Martinowitz, Israel
  14:15

- Questions and answers, and concluding remarks
  Chairmen
  14:35

- Symposium close
  14:45
### Technical Session Farhaty A 07:30–08:30

**Standardization of Thrombin Generation and first clinical applications**

**Chairman:** Claude Negrier, France

- **Welcome and Introduction**
  Claude Negrier, France 07:30

- **Pre-analytical and analytical standardization of Thrombin Generation towards clinical applications**
  Hugo Ten Cate, The Netherlands 07:35

- **Management of bleeding disorders using Thrombin Generation**
  Claude Negrier, France 07:55

- **Questions and Answers**
  Claude Negrier, France; Hugo Ten Cate, The Netherlands 08:15
TWO SCENARIOS. ONE SOLUTION.

New and improved INRatio®2 PT/INR Monitoring System

The INRatio®2 PT/INR system provides a simple and reliable point of care solution to improving the clinical effectiveness of Oral Anticoagulation Therapy. Healthcare Professionals can test and see results in seconds, allowing for immediate face to face dose adjustments with the patient. This simple handheld monitor can also empower patients to self-monitor their therapy in the comfort of their own home.

The INRatio®2 system produces quality assured lab-accurate results in just 60 seconds. Including a unique two level quantitative Quality Control system on every strip, the INRatio®2 system saves time and money. By allowing for more frequent testing, INRatio®2 enables patients to remain in therapeutic range for longer and, as a result, reduces clinical complications.

- The INRatio®2 system now has new heparin insensitive* test strips with an enhanced sample well requiring an even smaller drop of blood as low as 10µl, making INR testing even easier.

- The INRatio®2 system now has connectivity and data management solutions in which results can be downloaded to your PC via a data cable and tagged with Patient name, ID and DOB.

For further information please visit www.inratio2.com or e-mail info.cardiology@invmed.com

© 2010 Inverness Medical. All rights reserved. Inratio2 is a registered trademark of the Inverness Medical group of companies.

*ONF up to 2 Units INR up to 2 anti-Xa Units.
Sponsor & Exhibitor Profiles

Alfa Lab
El Safa Medical Tower
Hegaz Street-Mohandseen
Giza- Egypt
Tel: ++202 33363046
www.alfalaboratory.com

Alfa Lab is a shareholder company and is one of the most distinguished Medical laboratories in Egypt and in the Middle East. Since 1998, Alfa Lab has been participating in the private sector of medical services and is committed to the highest level of quality, thus offering first class services to its customers. There are 27 branches for Alfa Lab in Egypt and one in United Arab Emirates. There are 56 specialists working in the technical units together with 160 highly trained technologists. Alfa Lab has the Following Certificates: RIQAS ,EQAS & ISO 9001 – 2008

Baxter
Contact Person: Angela Overby
Title: Marketing Manager, Global Congress and Events
Telephone: 805-405-3481, Fax: 805-372-3602
Email: angela_overby@baxter.com
Company Address: One Baxter Way, Westlake Village, CA 91362 USA
www.Baxter.com

Baxter develops, manufactures and markets products with the aim of saving and sustaining the lives of people with hemophilia and other chronic medical conditions worldwide. Baxter provides therapies for hemophilia A and B, for inhibitor management, and is investigating possible therapies for von Willebrand’s Disease and other hematologic disorders.

Bayer Schering Pharma AG
Muellerstr. 178
13353 Berlin, Germany
www.bayerscheringpharma.de

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life.
Sponsor & Exhibitor Profiles (Continued)

**Boehringer Ingelheim GmbH**

Binger Straße 173 Ingelheim Germany 55216
Tel: +49-6132-77-0, Fax: +49-6132-77-3000
Email: info@boehringer-ingelheim.com
www.boehringer-ingelheim.com

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies with net sales of 11.6 billion Euros. It operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Pradaxa® (dabigatran etexilate) is at the forefront of a new generation of oral anticoagulants. It is being evaluated in a variety of thromboembolic disorders while it is already approved for the primary prevention of venous thromboembolic events in adults following elective total hip or knee replacement surgery.

**Cellix**

Vivienne Williams, Chief Executive Officer
Email: v.williams@cellixltd.com
Tel: +353-1-896-3182
Dmitry Kashanin, Chief Technology Officer
Email: d.kashanin@cellixltd.com
Tel: +353-1-896-4016

Cellix is an Irish based company producing a range of precise microfluidic pumping solutions and biochips for applied biological research and drug screening. Cellix’s customised platforms provide continuous blood flow (via Mirus Nanopump) and simulate blood vessels (via capillaries in Vena8 and VenaEC biochips) in a robust in vitro micro-environment. Investigation of platelet biology and thrombi formation is a key application of our technology where customers cite the “reduction in blood sample required; ease of use and physiological relevance” of the assays as being of key importance. Customers include academics, blood centres and pharmaceutical companies around the world. Cellix sells directly in the US and via a network of distributors in Europe and Asia. Distributors include: UK – Stratech Scientific; Sweden – Electra-Box Diagnostica; Germany – Chromaphor; Switzerland – CBI Medical; Austria – THP Medical; Italy – Crisel Instruments; Singapore – Precision Technologies; Japan – ShoshinEm and IEDA Trading Corp.; China – WillTek; Passkey Instruments and Qichi Instruments; Korea – Daymoon Industries and Taiwan – Major Instruments.
**CSL Behring**

www.cslbehring.com

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients’ lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company’s therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns.

The company also operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia.

**DiaMed**

Haematologic Technologies, Inc.

57 River Road
Essex Junction, Vermont 05452 USA

www.haemtech.com

Haematologic Technologies, Inc. (HTI) is a manufacturer that specializes in the isolation and characterization of high quality, plasma proteins which are intended for in vitro research use. HTI’s emphasis is focused on proteins involved in the regulation of blood coagulation and fibrinolysis, as well as the regulation of bone metabolism. The HTI product line consists of over 150 highly purified and well-characterized plasma proteins and a complement line of monoclonal and polyclonal antibodies. HTI also offers immunochemically-depleted factor deficient plasmas as well as customized blood collection tubes.
**Sponsor & Exhibitor Profiles** (Continued)

**Inverness Medical Innovations**
c/o Biosite International
Rue des Vignerons 1A
1110 Morges
Switzerland
www.invernessmedical.com

Inverness Medical is a world leader in diagnostic products to assist laboratory and healthcare professionals in both preventative and interventional medicine, providing qualitative and quantitative results. Our focus is in the broad clinical fields of Women’s Health, Oncology, Drugs of Abuse, Infectious Disease and Cardiology.

Inverness Medical’s cardiovascular portfolio includes anticoagulant therapy management (PT/INR) with the INRatio®2 System.

**Instrumentation Laboratories**
180 Hartwell Road
Bedford, MA 01730
1-800-955-9525
www.ilus.com

As a worldwide leader in clinical diagnostics, Instrumentation Laboratory (IL) is passionate about delivering the most innovative solutions to address a range of hemostasis testing needs. The advanced ACL™ family of new-generation systems brings complete automation to the hemostasis lab—including the ACL TOP® Family of Hemostasis Testing Systems, comprised of the new ACL TOP 700/700 LAS, ACL TOP 500 CTS; and, the ACL AcuStar™, the first fully automated, chemiluminescent analyzer for hemostasis specialty testing. Combined with the HemosIL line of reagents, a comprehensive panel of fully automated assays, IL offers complete disease state management for the hemostasis lab.
Sponsor & Exhibitor Profiles (Continued)

ISTH 2011
Secretariat of ISTH 2011
c/o Japan Convention Services, Inc.
1-4-2 Kasumigaseki, Chiyoda-ku Tokyo Japan 100-0013
www.isth2011.com

The XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH 2011) and the 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH will be held in Kyoto, Japan. In addition to an excellent program of basic and clinical science, delegates will find Kyoto to be a charming city bejeweled by more than 2,000 temples and shrines. Your experience in Kyoto, which had been Japan’s capital for more than eleven centuries, will be precious and unforgettable. See you next summer!

JTH
Commonwealth Bldg., 5th Floor, Du Cane Rd
London, W12 ONN
UK
www.journalth.com

Visit the Journal of Thrombosis and Haemostasis booth to find out more about the official journal of the ISTH and one of the leading titles in the field. Now with an Impact Factor of 6.291 (2008), the Journal of Thrombosis and Haemostasis is the essential resource for all involved in thrombosis, bleeding disorders and vascular biology. Pick up your sample copy and speak to a member of the editorial team.

LEO Pharma
Industriparken 55
DK-2750 Ballerup Denmark
Tel: +45 44 94 58 88
www.leo-pharma.com

Since the 1940s LEO Pharma has been committed to scientific research in the field of thrombosis and haemostasis.

innohep® (tinzaparin sodium) is one of the leading low molecular weight heparins used in the treatment and prevention of pulmonary embolism and deep vein thrombosis.

LEO Pharma is an independent company, solely owned by the LEO Foundation. To obtain more information on all our products, please visit our exhibition or www.leo-pharma.com.
**Multiplate group**  
Reichenbachstrasse 27  
80469 Munich  
Germany  
[www.multiplate.net](http://www.multiplate.net)

The Multiplate® platelet function analyzer is highly sensitive for the detection of aspirin, clopidogrel, prasugrel, IIbIIIa-antagonists and platelet disorders. The largest study to date evaluating the clinical impact of clopidogrel resistance has proven that CAD patients, stratified as inadequate responders exhibited a 9.4 fold increased risk of early stent thrombosis. Clinical predictivity for ischemic and bleeding events was demonstrated in several studies.

With more than 600 installations in the market Multiplate® is a widely applied whole blood platelet aggregometer and market leader for the monitoring of ADP receptor antagonists in Europe. A newer approach is a quick functional HIT test.

**Novo Nordisk Health Care AG**  
Andreasstrasse 15  
CH-8050 Zurich  
Switzerland  
[www.novonordisk.com](http://www.novonordisk.com)

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Octapharma AG
Seidenstrasse 2, 8853 Lachen Switzerland
www.octapharma.com

Octapharma AG, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality plasma derivatives. The Octapharma product portfolio is focused on plasma derivatives for treatment in coagulation disorders, immunotherapy and intensive care and emergency medicine. Our coagulation product portfolio consists of: wilate®, new generation treatment for von Willebrand patients. octanate®, VWF-stabilized FVIII to prevent and cure FVIII-Inhibitors. octanine F® and nanotiv®, high purity SD-treated and nano-filtered Factor IX concentrates. octaplex®, state-of-the-art human prothrombin complex concentrate.

Pentapharm DSM Nutritional Products AG
Engelgasse 109
CH-4002 Basel/Switzerland
Tel: +41 61 706 48 48, Fax: +41 61 706 48 00
www.pentapharm.com

Pentapharm is a manufacturer of reagents for blood coagulation diagnostics: Test kits e.g. Pefakit® APC-R Factor V Leiden, PiCT® (for anti-FIIa and FXa drug monitoring), Reptilase Time, in-TDT®, FXIII functional assay or OEM products. Reagents (from research to bulk quantities) including custom development and production: synthetic chromogenic and fluorogenic substrates, inhibitors, snake venom enzymes. 
Active pharmaceutical ingredients: aprotinin, peptides and snake venom derived enzymes (Batroxobin; Haemocoagulase ) and custom synthesis of peptides and small organic molecules.
**Pfizer**
Africa-Middle East Regional Office
Dubai Healthcare City
Al Faris Building
Dubai, UAE
[www.pfizer.com](http://www.pfizer.com)

Founded in 1849, Pfizer is the World’s largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and provide better quality healthcare and health system support.

Wyeth is now a wholly owned subsidiary of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory obligations.

**Precision BioLogic Inc.**
140 Eileen Stubbs Avenue
Dartmouth, NS  B3B 0A9
Canada
[www.precisionbiologic.com](http://www.precisionbiologic.com)

Precision BioLogic Inc. (PBI) develops, manufactures and sells diagnostic products used for testing in special coagulation laboratories around the globe. Our unique approach to serving customers is built on our superior products, commitment to customer support and attention to detail. Over the past 17 years, our CRYOcheck™ frozen controls, calibrators and regents have become synonymous with quality. Today, we are growing our product base to help meet customers’ coagulation needs by adding more in vitro diagnostics, including our line of clot-based diagnostic kits.
sanofi aventis
174, av. de France – 75013 PARIS – France
Contact Person: Joëlle Sissmann – Communication Department
joelle.sissmann@sanofi-aventis.com
Tel: +33.1.53.77.42.41, Fax: +33.1.53.77.91.77
http://en.sanofi-aventis.com
sanofi-aventis is a diversified global healthcare company, focused on patients’ needs.

The leading pharmaceutical company in Europe and in emerging markets, sanofi-aventis is the fourth largest worldwide (source IMS 2008).

A worldwide presence, market leadership in vaccines with the Group’s vaccine division Sanofi Pasteur, major biological products and a strong and long-established presence in emerging markets: these are the core strengths of sanofi-aventis. Company business activities also include consumer healthcare (OTC) products, generics and animal health products.

Our business strategy is based on three key themes to reach and deliver sustainable growth: increasing innovation in Research & Development, adapting our structures to meet the challenges of the future and exploring external growth opportunities.

As a healthcare leader, sanofi-aventis is concerned about global public health issues and implements a regional approach to markets to make the most of local opportunities. We are evolving towards a regional business model to leverage our overall regional presence much more effectively and seize all local growth opportunities.

Schattauer GmbH
Hoelderlinstrasse 3
70174 Stuttgart GERMANY
www.thrombosis-online.com
THROMBOSIS AND HAEMOSTASIS publishes original articles with a broad scope in basic research and clinical studies in vascular biology and medicine. Categories include: blood coagulation, fibrinolysis and cellular haemostasis; platelets and blood cells; wound healing and inflammation/infection; endothelium and vascular development; cardiovascular biology and cell signaling; cellular proteolysis and oncology; new technologies, diagnostic tools and drugs.
Sponsor & Exhibitor Profiles (Continued)

Siemens Healthcare Diagnostics Inc.
1717 Deerfield Road
Deerfield, IL 60015-0778 USA
[www.siemens.com/diagnostics](http://www.siemens.com/diagnostics)

Siemens Healthcare Diagnostics is a leading global clinical diagnostics company. We are committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment, and monitoring of patients.

Our comprehensive portfolio of performance-driven systems, unmatched menu offering, and information technology (IT) solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency, and support improved patient care.

The depth and breadth of our diagnostic solutions are designed to meet the growing demands of our customers, today and tomorrow.

Stago
9 rue des Frères Chausson
92600 Asnières sur Sein, France
Tel: +33 (0)1.46.88.20.20
[www.stago.com](http://www.stago.com)

Stago dedicates its research and innovative skills to develop and improve the accuracy of the medical diagnostic. The firm formulates, manufactures and markets worldwide, a broad range of reagents (routine & research) and fully automated systems for haemostasis & thrombosis.

Thanks to its haemostasis expertise, Stago is recognized and is in position to cooperate with the scientific community worldwide.

Affiliates in USA, China, UK, Australia/NZ, Canada, UAE – wide network of distributors (> 100 countries)

BioCytex and Thrombinoscope, both Stago group companies, develop advanced research tools in field of cellular biology and Thrombin Generation.
Technoclone
Brunner Str. 59/5
1230 Vienna, Austria
Tel: +43 1 86 373-0
www.technoclone.com

Technoclone is a world leading producer not only of ELISA systems, but also of global and special coagulation tests, control and reference plasmas. Ceveron alpha, a coagulation analyzer, offers the unique feature of fully automated thrombin generation measurement in the routine. Another innovation is the Ceveron MFU 500, a microparticle filtration unit which can identify microparticles thrombogenicity in conjunction with the Technothrombin MP. Furthermore Technoclone provides a complete range of ADAMTS13 ELISAs and FXIII assays. With the new TECHNOVIEW control and calibration plasma product range we were able to expand the portfolio for anticoagulant therapy monitoring.
Exhibitor Floor Plan

The Exhibit Area is located in the Nile Expo of the Grand Hyatt, along with The Bayer Cyber Café and the Seat Retreat relaxation area.

Exhibit Hours:
Saturday, 22 May 10:00–18:00
Sunday, 23 May 10:00–18:00
Monday, 24 May 10:00–18:00
Tuesday, 25 May 10:00–13:00

The Nile Expo is on the 6th Floor.
## Exhibitors

<table>
<thead>
<tr>
<th>Exhibitor:</th>
<th>Booth Number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novo Nordisk</td>
<td>1</td>
</tr>
<tr>
<td>Baxter Healthcare</td>
<td>2</td>
</tr>
<tr>
<td>Pentapharm</td>
<td>3</td>
</tr>
<tr>
<td>Cellix</td>
<td>4</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>5</td>
</tr>
<tr>
<td>Inverness Medical Innovations</td>
<td>6</td>
</tr>
<tr>
<td>Instrumentation Laboratories</td>
<td>7</td>
</tr>
<tr>
<td>DiaMed</td>
<td>8</td>
</tr>
<tr>
<td>Pfizer</td>
<td>9</td>
</tr>
<tr>
<td>Leo Pharma</td>
<td>10</td>
</tr>
<tr>
<td>Stago</td>
<td>11</td>
</tr>
<tr>
<td>Technoclone</td>
<td>12</td>
</tr>
<tr>
<td>Precision BioLogic</td>
<td>13</td>
</tr>
<tr>
<td>Siemens</td>
<td>14</td>
</tr>
<tr>
<td>Multiplate</td>
<td>15</td>
</tr>
<tr>
<td>Journal of Thrombosis and Haemostasis</td>
<td></td>
</tr>
<tr>
<td>ISTH 2011</td>
<td></td>
</tr>
</tbody>
</table>

*Journal of Thrombosis and Haemostasis* Farhaty Foyer, Fifth Floor

*ISTH 2011* Farhaty Foyer, Fifth Floor
# Researching more ways to improve patients’ lives

Baxter is a leader in hemophilia research and development, working to further our understanding of, and optimize treatment for, hemophilia and other bleeding disorders.

All of our work deepens our understanding of hemophilia and other coagulation disorders and the ways in which various potential new therapies may improve the lives of people living with these conditions.

## Research and development initiatives*

<table>
<thead>
<tr>
<th>Initiative</th>
<th>Status</th>
<th>Phase</th>
<th>Status</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemophilia A Management: Based on Baxter’s plasma and albumin-free platform technology</td>
<td></td>
<td>PRE-CLINICAL</td>
<td></td>
<td>CLINICAL</td>
</tr>
<tr>
<td>Recombinant factor VIII: Longer-acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinant factor VIII: Non-intravenous alternative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IV Comparative Surgery Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IIIb Previously Untreated Patients (PUPs) Study (CLOSED)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IV Prophylaxis Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IV ITI Surveillance Study (PAIR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IV Surveillance Studies (PASS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhibitor Management with Bypassing Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinant factor VIIa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IIIb Prophylaxis Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IV Safety Surveillance Study (PASS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IV Surgery Study (SURF) (CLOSED)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemophilia B Management</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinant factor IX</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinant factor IX: Longer-acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematologic Management with Novel Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADAMTS13</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-anticoagulant sulphated polysaccharides (NASP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Von Willebrand’s Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I Recombinant von Willebrand factor**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Studies are investigational. Safety and efficacy have not been established. This is not a comprehensive list, additional studies are ongoing.

** Based on Baxter’s plasma- and albumin-free platform technology.

---

Baxter is a trademark of Baxter International Inc.
© Copyright (March 2010) Baxter Healthcare Corporation. All rights reserved. GBL 1012.